

# **IPOPEMA Daily**

### **CORPORATE NEWS CEE**

#### **BANKS & FINANCIALS**

PZU - Provided range of dividend in solvency report

#### **OIL & GAS & CHEMICALS**

ORLEN – New management and a new CEO are to be appointed next week GRUPA AZOTY – FY2023 results publication date changed to 29 April 2024

#### UTILITIES

PGE - 4Q23 actual results in line with preliminary print

PGE - Appointment of deputy CFO

MO BRUK - Court overturned decision regarding increased fee of PLN 19.1m

#### **METALS & MINING**

JSW - Changes in the supervisory board

#### **CONSUMER STAPLES**

DINO POLSKA- The company opened 32 new stores in 1Q24 PODRVAKA – Podravka proposes EUR 3.2 per share as a cash dividend for 2024

#### **E-COMMERCE**

ANSWEAR - 1Q24 revenues

#### **VIDEO GAMES**

ARTIFEX MUNDI - 4Q23 conference highlights

#### **TECHNOLOGY**

SUNEX - Signing of letter of intent

#### **TELECOMS, MEDIA & IT**

WIRTUALNA POLSKA HOLDING – Update on new two TV channels in cable/satellite access DATAWALK – New patent in US

ATENDE - Change on CEO post

### **BIOTECHNOLOGY & HEALTHCARE**

VOXEL – 4Q23 earnings above consensus, below our expectations, strong OpCF NEUCA – Plans to keep market shares, focus on generics and possible M&A KRKA – Krka proposed EUR 7.5 per share as a cash dividend for 2024, up 13.6% y/y

### **REAL ESTATE**

LOKUM DEWELOPER – Pre-sales in 1Q24 decreased by 55% y/y, deliveries up by 30% y/y

### **INDUSTRIALS**

ARCTIC PAPER – Published 4Q23 results GRUPA KETY – New shares registered by KDPW Messer Tehnogas – Tehnogas reports strong non-consolidated numbers for 2023

### **TRAVEL & LEISURE**

AIRCRAFT SERVICES – Ryan Air and Wizz Air monthly data RAINBOW TOURS – 4Q23 preliminary consolidated net profit amounted to PLN 4.8m


#### **OTHERS**

DELKO – EGM scheduled on 8 May 2024

#### **MACRO NEWS**

POLAND – Uncertain inflation outlook still key for MPC ROMANIA – Rates stable but first cut looming

| POLAND                           | Last price | 1D         | 1M    | YTD     |
|----------------------------------|------------|------------|-------|---------|
| WIG20                            | 2,469      | 1.5%       | 4.3%  | 5.4%    |
| WIG                              | 83,867     | 1.2%       | 4.1%  | 6.9%    |
| mWIG40                           | 6,453      | 0.9%       | 4.6%  | 11.5%   |
| sWIG80                           | 24,300     | 0.2%       | 2.1%  | 6.1%    |
| Daily Turnover                   | PLN m      | Most activ | ⁄e    | PLN m   |
| WIG                              | 1,523.0    | KGH PW     |       | 282.5   |
| WIG20                            | 1,257.6    | DNP PW     |       | 154.8   |
| mWIG40                           | 178.6      | PKO PW     |       | 137.8   |
| sWIG80                           | 62.3       | PKN PW     |       | 129.6   |
| Top Gainers                      | % Chng     | Top Lagge  | ers   | % Chng  |
| KRU PW                           | 6.4%       | ALE PW     |       | -1.4%   |
| KGH PW                           | 5.4%       | BDX PW     |       | -0.1%   |
| KTY PW                           | 3.9%       | MBK PW     |       | 0.1%    |
| HUNGARY                          | Last price | 1D         | 1M    | YTD     |
| BUX                              | 66,625     | -0.3%      | 1.2%  | 9.9%    |
| BUMIX                            | 6,221      | 0.7%       | 7.3%  | 17.7%   |
| Daily Turnover                   | HUF m      | Most activ | ⁄e    | HUF m   |
| BUX                              | 6,221.2    | OTP BANK   | <     | 16774.9 |
| Top Gainers                      | % Chng     | Top Lagge  | ers   | % Chng  |
| MASTERPL HB                      | 7.9%       | RICHT HB   |       | -1.2%   |
| PANNONIA HB                      | 1.9%       | OPUS HB    |       | -1.1%   |
| MTELEKOM HB                      | 1.1%       | OTP HB     |       | -1.0%   |
| CZECH REPUBLIC                   | Last price | 1D         | 1M    | YTD     |
| PX                               | 1,529      | 0.6%       | 4.9%  | 8.1%    |
| Daily Turnover                   | CZK m      | Most activ |       | CZK m   |
| PX                               | 292,732.8  | KOMB CP    |       | 101.5   |
| Top Gainers                      | % Chng     | Top Lagge  | ers   | % Chng  |
| CEZ CP                           | 1.2%       | TABAK CP   | 1     | -0.6%   |
| RBAG CP                          | 0.9%       | VIG CP     |       | -0.4%   |
| KOMB CP                          | 0.6%       | KOFOL CF   |       | -0.3%   |
| ROMANIA                          | Last price | 1D         | 1M    | YID     |
| BET                              | 17,072     | 0.2%       | 5.4%  | 11.1%   |
| Daily Turnover                   | RON m      | Most activ | ⁄e    | RON m   |
| BET                              | 39,652.8   | H2O RO     |       | 10.1    |
| Top Gainers                      | % Chng     | Top Lagge  | ers   | % Chng  |
| M RO                             | 3.8%       | TEL RO     |       | -1.1%   |
| SFG RO                           | 2.6%       | EL RO      |       | -0.7%   |
| ONE RO                           | 2.4%       | SNN RO     |       | -0.6%   |
| Currency                         | Last price | 1D         | 1M    | YTD     |
| EUR/PLN                          | 4.2909     | 0.0%       | -0.5% | -1.2%   |
| USD/PLN                          | 3.9593     | 0.0%       | -0.3% | 0.6%    |
| EUR/HUF                          | 392.17     | -0.1%      | -0.4% | 2.3%    |
| CHF/PLN                          | 4.3923     | 0.1%       | -2.3% | -6.1%   |
| EUR/USD                          | 1.0837     | 0.0%       | -0.2% | -1.8%   |
| Money markets                    |            | 2Y         | 5Y    | 10Y     |
|                                  |            |            |       |         |
| Reference rate * intraday prices | 5.75       | 5.00       | 5.33  | 5.47    |





**KGHM :** broke almost 3-year descending trendline - supported copper and international peers

### CORPORATE NEWS CEE

### **BANKS & FINANCIALS**

#### PZU - Provided range of dividend in solvency report

In solvency report PZU provided the range of the planned dividend, i.e. DPS ranging from PLN3.34 p/s to PLN 5.34 p/s. PZU also showed an intermediate variant of PLN 4.6 p/s (unit profit for 2023 not increased by the unpaid part of PZU's net profit from 2022).

When calculating the solvency coefficient, the highest possible dividend was taken into account. At the same time, the management board emphasized that the decision on the distribution of profit for 2023 has not been made.

*Opinion: Positive.* The proposed range is slightly higher than our expectations min. PLN3.21 p/s max. PLN 5.14 p/s, our estimate is PLN 4.20 p/s which seems too conservative, and the consensus on the bloom reported is much lower PLN 3.1 p/s.

Marta Czajkowska-Bałdyga, +48 22 236 9231

### **OIL & GAS & CHEMICALS**

#### ORLEN - New management and a new CEO are to be appointed next week

Minister of State Assets Borys Budka disclosed to the press that next week, a new management team and CEO are expected to be appointed.

**Opinion: Neutral.** Earlier local press mentioned Krzysztof Zamasz (ex-ENEA, ex-Tauron) and Ireneusz Fafara (ex-Orlen Lietuva, ex-BGK) as strong candidates for the CEO role at Orlen.

Tomasz Kasowicz, +48 22 236 94 14

#### GRUPA AZOTY – FY2023 results publication date changed to 29 April 2024

Grupa Azoty has announced that its FY2023 results, instead of being published on the earlier planned date of 10 April 2024, will now be released on 29 April 2024.

Opinion: Neutral.

Tomasz Kasowicz, +48 22 236 94 14

### **UTILITIES**

### PGE – 4Q23 actual results in line with preliminary print

PGE reported 4Q23 actual results in line with preliminary print.

- PGE electricity generation arrived at 15.6TWh in 4Q23, (-12% y/y) and 56.8TWh in FY (-14% y/y) declined mainly due to curtailment of lignite generation.
- Recurring EBITDA at PLN 2.1bn (+256% y/y) in 4Q23 and at record-high of PLN 10.7bn (+51% y/y) in FY 23, jumped up y/y on strong improvement of Conventional Generation and District Heating margins. Positive effect of inclusion of new business segment Railway Energy Services and higher tariffs in Distribution. Decline in Renewables on lower SPOT prices, Supply significantly hit by provisions for regulated tariffs and lower margins.
- Reported EBITDA at PLN 1.7bn (+401% y/y) in 4Q23 and at PLN 10.0bn (+16% y/y) in FY 23, affected by one-offs including mainly reclamation provision.
- PLN 11.1bn net debt at the end of 2023, significantly higher q/q on cash settlement of CO2. Net economic debt at PLN 22.0bn higher q/q mainly on change in working capital.

Conventional Generation recurring EBITDA was up to PLN 0.4bn (vs. loss of PLN 0.4bn in Q4 22) in Q4 and up to PLN 2.1bn (+238% y/y) in FY 23. Margins were improved y/y despite lower volumes as results in 2022 were hit by sharp rise in fuel costs. Results were also positively affected by revenues from ancillary services (chiefly due to reallocation of production).

- District Heating results were strong both in Q4 PLN at PLN 0.7bn (vs. loss of PLN 0.01bn in Q4 22) and FY 23 at PLN 2.1bn (vs. PLN 0.03bn in Q4 22). Profits were driven up by higher heat tariffs, higher electricity prices and increase in electricity production due to better profitability of gas generation. Strong y/y dynamics was also effect of low-base from 2022, as in 2022 sharply rising fuels and CO2 costs were only to small extend transferred in heat tariffs.
- RES segment recurring EBITDA declined in Q4 down to PLN 0.3bn (-31% y/y) and to PLN 1.1bn in FY 23 (-38% y/y mainly on lower revenues from sale of electricity due to lower SPOT prices.
- Supply segment posted losses both in Q4 at PLN -0.5bn (profit of PLN 0.3bn in Q4 22) and FY 23 at PLN -0.1bn (profit of PLN 2.0bn in FY 22). EBITDA was affected by the lower margin on the sale of electricity and provisions for household tariff for 2024 (PLN -0.8bn) and for the Regulation of the Minister for Climate and Environment on tariffs (PLN -0.5bn).
- Distribution recurring EBITDA was slightly lower in Q4 at PLN 0.7bn (-5% y/y) on rising costs of balancing energy and significantly higher at PLN 3.9bn (+39% y/y) in FY 23 on positive effect of higher distribution tariff due to rising WACC.
- Expenditures on investments (on accrual basis) in PGE Group ramped up to PLN 10.1bn (+43% y/y) in FY 23 mainly on raising outlays for investment in Distribution and RES segments. On the top of that appeared expenditures of a new segment Railway Energy Services.

Figure 1. PGE 4Q23 actual results overview (PLN m)

|                              | 1Q22A  | 2Q22A  | 3Q22A  | 4Q22A  | 1Q23A  | 2Q23A  | 3Q23   | 4Q23A  | Y/Y     | Q/Q 4  | Q23preli | diff  |
|------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|---------|--------|----------|-------|
| Revenues                     | 16,897 | 15,728 | 19,355 | 21,455 | 27,208 | 22,352 | 21,515 | 24,889 | 16.0%   | 15.7%  | na       |       |
| EBIT                         | 1,550  | 2,704  | 805    | -760   | 2,343  | 1,206  | 1,206  | -8,186 | na      | na     | na       |       |
| EBITDA (reported)            | 2,615  | 3,777  | 1,926  | 339    | 3,427  | 2,445  | 2,458  | 1,698  | 400.9%  | -30.9% | 1,698    | 0.0%  |
| Mininng and generation       | 438    | 2,092  | 157    | -622   | 909    | 104    | 310    | 149    | na      | -51.9% | 149      | 0.0%  |
| Heat                         | 201    | -142   | -10    | -10    | 916    | 312    | 89     | 635    | na      | 613.5% | 635      | 0.0%  |
| Renewables                   | 500    | 341    | 561    | 393    | 436    | 243    | 167    | 268    | -31.8%  | 60.5%  | 268      | 0.0%  |
| Wholesale                    | 593    | 583    | 509    | 358    | -254   | 371    | 387    | -508   | -241.9% | na     | -508     | 0.0%  |
| Distribution                 | 798    | 674    | 668    | 710    | 1,274  | 1,246  | 1,357  | 1,246  | 75.5%   | -8.2%  | 1,246    | 0.0%  |
| Other                        | 85     | 229    | 41     | -490   | 146    | 169    | 148    | -92    | -81.2%  | na     | -92      | 0.0%  |
| recurring EBITDA             | 2,596  | 1,616  | 2,328  | 580    | 3,427  | 2,859  | 2,450  | 2,067  | 256.4%  | -15.6% | 2,067    | 0.0%  |
| Adjusted net income          | 1,027  | 2,272  | 698    | -585   | 1,724  | 397    | 953    | -1,095 | na      | na     |          |       |
| Reported Net income          | 1,022  | 2,266  | 654    | -614   | 1,724  | 352    | 953    | -8,041 | na      | na     | -8,041   | 0%    |
| EBITDA margin                | 15.5%  | 24.0%  | 10.0%  | 1.6%   | 12.6%  | 10.9%  | 11.4%  | 6.8%   |         |        | na       |       |
| Net profit margin            | 6.0%   | 14.4%  | 3.4%   | -2.9%  | 6.3%   | 1.6%   | 4.4%   | -32.3% |         |        | na       |       |
| Key operating figures        | 1Q22A  | 2Q22A  | 3Q22A  | 4Q22A  | 1Q23A  | 2Q23A  | 3Q23A  | 4Q23A  | Y/Y     | Q/Q 4  | Q23preli |       |
| Generation volume (TWh, net) | 17.32  | 15.00  | 16.02  | 17.79  | 15.72  | 12.30  | 13.10  | 15.65  | -18.2%  | 6.5%   | 15.68    | -0.2% |
| Distribution volume (TWh)    | 9.79   | 8.83   | 8.93   | 9.52   | 9.47   | 9.35   | 9.64   | 10.42  | 8.0%    | 3.1%   | 10.44    | -0.2% |
| Sales volume - retail (TWh)  | 9.10   | 8.36   | 8.26   | 8.56   | 8.87   | 8.61   | 8.49   | 8.75   | 2.8%    | -1.4%  | 8.73     | 0.2%  |

Source: Company, IPOPEMA Research

*Opinion: Neutral.* The company holds an analyst's meeting at 10:00 CEST <a href="https://infostrefa.tv/pge/">https://infostrefa.tv/pge/</a>

Robert Maj, +48 22 236 92 90;

#### PGE - Appointment of deputy CFO

Company's supervisory board appointed Mrs. Renata Czech to the management boars as vice CFO, effective as of 15 April 2024.

### MO BRUK - Court overturned decision regarding increased fee of PLN 19.1m

The Regional Administrative Court in Wroclaw has overturned the decision of the Local Government Appeal Board in Wroclaw regarding the increased fee of PLN 19.1m for waste storage in 2017.

### **METALS & MINING**

#### JSW - Changes in the supervisory board

EGM appointed Mr. Paweł Bieszczad, to the supervisory board on 4 April 2024.

### **CONSUMER STAPLES**

#### DINO POLSKA- The company opened 32 new stores in 1Q24

The company opened 32 new stores in 1Q24 (vs. 54 in 1Q23). Its network numbered 2,438 stores at the end of 1Q24 ( $\pm$ 10.3% y/y;  $\pm$ 228 stores in full-year terms). The selling area amounted 960.9 thousand sqm ( $\pm$ 10.5% y/y).

Opinion: Reported pace of growth was the lowest in company's history as it stood at bearly +10% y/y and was below our expectations (we anticipated 45-50 new stores). We note that during recent conference call, Mr. Michal Krauze (the CFO) stated that the number of net openings in 1Q24 will be lower than in previous quarters (due to unfavorable weather conditions, which affected the construction process). Concurrently, he convinced that the group will open slightly above 250 stores in 2024E (vs. 250 units in 2023)

Adrian Górniak, +48 514 995 073

Figure 2. Dino - no. of stores (units)




Figure 3. Dino - selling area (k sqm)



Source: Company, IPOPEMA Research

#### PODRVAKA – Podravka proposes EUR 3.2 per share as a cash dividend for 2024

Podravka, Croatian diversified packed food company proposed EUR 3.2 per share as a cash dividend for 2024. Record date is on 14th June. The proposed amount implies 47% payout ratio from 2023 profit (normalized – excluding tax gain).

**Opinion. Neutral.** With the stock price up 70% over the last 12 months, proposed amount at EUR 3.2 per share offers only 2% gross yield. It is only slightly higher vs. our target at EUR 3.0 per share. The payout ratio is however hiked to 47% vs. earlier 38%.

Vladan Pavlovic, +381 65 25 15 979

### **E-COMMERCE**

### ANSWEAR - 1Q24 revenues

Answear reported that 1Q24 revenues came in at PLN 289m (+7% y/y), while online sales amounted to PLN 280m (+5% y/y). The company pointed that revenues in 1Q24 were negatively affected by lower consumer demand related to macro situation (and limited purchase of AW23 collection), lower demand in Ukraine and strengthening PLN vs. other currencies (adj. growth rate of ca. +10% y/y).

500.0 450.0 400.0 350.0 300.0 250.0 200.0 100.0 50.0 0.0

Figure 4. Answear – quarterly revenues (PLNm)

Source: Company, IPOPEMA Research

**Opinion:** Negative, given lower y/y growth rate of revenues than in previous quarters (revenues increased by 29% y/y in 2023), although the company sees positive start of sale of SS24 collection and expects better results in 2Q24.

Marek Szymański, +48 22 236 9412

### **VIDEO GAMES**

### ARTIFEX MUNDI - 4Q23 conference highlights

Below are our main takeaways from Artifex Mundi's conference call held on 4 April 2024:

**Metagame.** CEO assumes that the implementation of the metagame into the Unsolved app provides a 100% potential for increasing lifetime value. The plan for the Unsolved metagame assumes that by the end of this year, the company will be achieving subsequent key milestones. At the turn of 2024/25, Artifex will already be collecting the first test results from players, and the full implementation of the metagame will be in the year 2025. Then, if the KPIs are good, Live-Ops activity will gradually increase.

**Unsovled new content.** The company plans to simultaneously expand content while working on the metagame, including by adding at least 10 to 12 new games, which is expected to translate into a several percent increase in LTV.

**RPG.** The CEO maintained that the company is at the stage of advanced production of the RPG game and that another round of player testing will be conducted at the end of the second quarter. According to the CEO, the company is close to the moment when it will start to publicize details of the RPG project.

**General outlook.** Furthermore, the company expects further revenue growth from Unsolved with lower revenues from premium game sales and plans to increase expenditures on expanding the player base, correlated with the situation in the advertising market and the evolution of the Unsolved LTV ratio.

Opinion: Supportive.

Michał Wojciechowski, +48 22 236 92 69 Marcin Nowak, +48 22 236 9244



### **TECHNOLOGY**

#### SUNEX - Signing of letter of intent

Company informed that the other party has signed a letter of intent, the subject of which is a potential transaction to acquire 100% of the shares in an Austrian company with an estimated value of EUR 2m. The planned acquisition of shares is to be carried out in stages within 3 years of the transaction.

### **TELECOMS, MEDIA & IT**

### WIRTUALNA POLSKA HOLDING - Update on new two TV channels in cable/satellite access

According to Wirtualnemedia.pl The National Broadcasting Council (KRRiT) has granted a licence for "Patronite Travel" TV channel from Wirtualna, while earlier in March granted licence for "Kabaret TV" (it was already launched on few cable networks). Earlier press.pl reported that "Kabaret TV" is going to show comedy sketches 24h per day (mainly recorded earlier content within library), while "Patronite Travel" will cover mainly travel related content (also mainly based on already owned library by WPL).

### Opinion: Neutral.

We find Wirtualna's TV related plans neutrally, as we do not expect them to have material impact on company's EBITDA generation (given planned content to be broadcasted and their limited reach). However, as currently Wirtualna includes former TV segment within media (and does not show separately TV related revenue/EBITDA), the launch of new TV channels may support top line growth in media segment (which usually is in market's focus).

We remind that Telewizja WP has not been a success so far (on our estimates it burned cash till date since late 2017's launch).

Marcin Nowak, +48 22 236 9244

#### DATAWALK - New patent in US

On 4 April 2024 DataWalk informed that received a patent in the United States Patent and Trademark Office titled "System And Methods For Determining Database Permissions".

### ATENDE – Change on CEO post

Atende Supervisory board dismissed Mr. Marcin Petrykowski from CEO post and appointed Mr. Jacek Szczepański, former deputy CEO.

### **BIOTECHNOLOGY & HEALTHCARE**

#### VOXEL - 4Q23 earnings above consensus, below our expectations, strong OpCF

Voxel reported 4Q23 results yesterday. Key points:

- In Diagnostics segment, Voxel reported PLN 87.3m sales (+19% y/y and -1% q/q), below our assumptions of PLN 90.7m. Segment's EBITDA stood at PLN 38.7m vs. PLN 31.2m in 4Q22 and our forecasts of PLN 44.3m. EBITDA margin stood at 48.6%, -1.7pp y/y and -4.2pp q/q.
- Total number of procedures stood at 106.7k (+8% y/y, flat q/q) including 4.4k PET/CT (+7% y/y), 65.4k MR (+10% y/y), 33.2k CT (+5% y/y) and 3.7k SPECT (+16% y/y).
- PET revenues stood at PLN 20.6m (+10% y/y), MR revenues at PLN 45.7m (+26% y/y), CT revenues at PLN 13.1m (+16% y/y) and SPECT revenues at PLN 3.8m (+58% y/y).
- Among other segments, Neurosurgery came above our forecasts with PLN 3.1m in sales and PLN 1.6m EBITDA (+18% y/y). Alteris revenue came down y/y but above our forecasts, with higher than expected 15.5% EBITDA margin. Hospital segment is presented as discontinued, in 4Q23 segment generated PLN 3.5m revenues and PLN 0.7m EBITDA.

• Overall, sales came at PLN 125.3m (-11% y/y, -5% on base without Hospital segment), 2% above consensus and 7% above our forecasts. Gross margin stood at 30.4% vs. 22.3% in 4Q22. EBITDA stood at PLN 40.3m (+40% y/y), 4% above consensus but 7% below our expectations. Financial costs stood at PLN 3.1m (including PLN 0.8m impairment on Vito-Med), slightly higher q/q, tax rate was 20.7% vs. 22.3% in 4Q22. Reported net profit reached PLN 22.4m vs. PLN 12.2m in 4Q22 and came 7% above consensus and 9% below our expectations.

• OCF came at PLN 50.9m vs PLN 49.4m in 4Q22. Net debt decreased q/q to PLN 55.6m from PLN 75.0m. Net debt/4Q-rolling EBITDA at 0.38x down from 0.56x.

Figure 5. Voxel 4Q23 results review

| PLN m                  | 1Q22  | 2Q22  | 3Q22  | 4Q22  | 1Q23  | 2Q23  | 3Q23  | 4Q23  | Y/Y    | Q/Q    | Cons. A | ctual vs I | popema . | Actual vs |
|------------------------|-------|-------|-------|-------|-------|-------|-------|-------|--------|--------|---------|------------|----------|-----------|
| PLINIII                | IQZZ  | ZŲZZ  | SQZZ  | 4022  | IQZS  | ZQZ3  | 3Q23  | 4Q23  | 1/1    | ŲŲ     | 4Q23E   | Cons.      | 4Q23E    | lpopema   |
| Revenue                | 99.9  | 76.1  | 98.6  | 140.1 | 96.8  | 100.9 | 127.9 | 125.3 | -10.6% | -2.1%  | 123.0   | 1.9%       | 117.5    | 6.6%      |
| Diagnostics            | 52.5  | 56.3  | 70.5  | 73.5  | 78.3  | 78.1  | 88.2  | 87.3  | 18.8%  | -1.0%  | -       | -          | 90.7     | -3.7%     |
| Neurosurgery           | 2.4   | 2.2   | 3.0   | 2.5   | 3.0   | 2.9   | 3.0   | 3.1   | 21.7%  | 2.7%   | -       | -          | 2.5      | 20.5%     |
| IT&infrastructure      | 35.0  | 18.0  | 26.4  | 58.6  | 11.1  | 19.2  | 31.8  | 39.5  | -32.5% | 24.4%  | -       | -          | 29.3     | 34.9%     |
| Hospital               | 32.3  | 5.8   | 8.3   | 9.1   | 8.7   | 9.5   | 8.5   | -     | -      | -      | -       | -          | -        | -         |
| Gross profit           | 22.8  | 14.7  | 29.6  | 31.2  | 29.2  | 29.8  | 39.2  | 38.1  | 22.2%  | -2.7%  | -       | -          | 41.4     | -8.0%     |
| Gross margin (%)       | 22.9% | 19.3% | 30.0% | 22.3% | 30.2% | 29.5% | 30.6% | 30.4% | 8.2%   | -0.2%  | -       | -          | 35.2%    | -4.8%     |
| EBITDA                 | 26.9  | 17.7  | 32.9  | 28.7  | 28.4  | 34.4  | 43.1  | 40.3  | 40.3%  | -6.4%  | 38.8    | 4.0%       | 43.4     | -7.1%     |
| Diagnostics            | 21.9  | 23.5  | 35.3  | 33.9  | 36.4  | 35.9  | 42.9  | 38.7  | 14.4%  | -9.6%  | -       | -          | 44.3     | -12.4%    |
| Neurosurgery           | 1.3   | 1.1   | 1.8   | 1.3   | 1.7   | 1.6   | 1.6   | 1.6   | 17.8%  | 0.7%   | -       | -          | 1.3      | 17.1%     |
| IT&infrastructure      | 10.1  | 2.3   | 2.6   | 5.1   | 1.7   | 2.4   | 4.3   | 6.1   | 20.6%  | 43.7%  | -       | -          | 3.0      | 106.4%    |
| Hospital               | -0.9  | -2.8  | -1.1  | -0.8  | -1.3  | -0.4  | -1.8  | -     | -      | -      | -       | -          | -        | -         |
| Other                  | -5.5  | -6.4  | -5.7  | -10.7 | -10.1 | -5.1  | -3.5  | -5.9  | -45.5% | 68.9%  | -       | -          | -5.1     | 13.8%     |
| EBITDA margin (%)      | 26.9% | 23.2% | 33.4% | 20.5% | 29.4% | 34.1% | 33.7% | 32.2% | 11.7%  | -1.5%  | 31.5%   | 0.6%       | 36.9%    | -4.7%     |
| D&A                    | 9.8   | 9.5   | 9.5   | 9.4   | 9.6   | 9.7   | 9.7   | 9.4   | 0.0%   | -3.7%  | 9.8     | -4.5%      | 9.7      | -3.2%     |
| EBIT                   | 17.1  | 8.2   | 23.5  | 19.4  | 18.9  | 24.7  | 33.4  | 31.0  | 59.8%  | -7.2%  | 29.0    | 6.8%       | 33.7     | -8.2%     |
| EBIT margin (%)        | 17.1% | 10.8% | 23.8% | 13.8% | 19.5% | 24.4% | 26.1% | 24.7% | 10.9%  | -1.4%  | 23.6%   | 1.1%       | 28.7%    | -4.0%     |
| Financials, net        | -2.5  | -2.3  | -3.2  | -3.2  | -3.0  | -2.5  | -2.0  | -3.1  | -3.6%  | 52.6%  | -       | -          | -3.4     | -8.6%     |
| Pre-tax income         | 14.6  | 5.9   | 20.2  | 16.2  | 15.9  | 22.2  | 31.3  | 27.9  | 72.5%  | -11.1% | -       | -          | 30.3     | -8.1%     |
| Tax                    | -2.9  | -1.0  | -3.8  | -3.6  | -3.9  | -4.9  | -7.8  | -5.8  | 60.3%  | -25.7% | -       | -          | -5.8     | 0.2%      |
| Effective tax rate (%) | 19.5% | 17.8% | 18.7% | 22.3% | 24.4% | 22.0% | 24.8% | 20.7% | -1.6%  | -4.1%  | -       | -          | 19.0%    | 1.7%      |
| Net income             | 11.5  | 4.6   | 16.1  | 12.2  | 11.6  | 17.0  | 23.1  | 22.4  | 83.1%  | -3.2%  | 21.0    | 6.7%       | 24.6     | -8.8%     |
| Net margin (%)         | 11.5% | 6.0%  | 16.3% | 8.7%  | 12.0% | 16.9% | 18.1% | 17.9% | 9.1%   | -0.2%  | 17.1%   | 0.8%       | 20.9%    | -3.0%     |

Source: Company, PAP, IPOPEMA Research

**Opinion:** Slightly positive. 4Q23 results were good, a few % above consensus. Our forecast was the highest in the consensus, reported results were a few percent below our expectations, mainly due to lower EBITDA margin in the diagnostics segment. On the cost side, we can see the effect of wage increases. The Alteris and Neurosurgery segments surprised positively. Once again, the company showed a strong OpCF, giving Voxel room to pay a solid dividend, acquisition activity and greater investment in new clinics.

Łukasz Kosiarski, +48 882 108 382

### NEUCA - Plans to keep market shares, focus on generics and possible M&A

Key points from yesterday's chat with Management on Strefa Inwestorów:

- Neuca expects further backlog growth and improved profitability in the clinical trials segment.
- Market share declines in 4Q23 are due to the introduction of AdA 2.0, some nonnetwork pharmacies moved to networks, additionally Neuca cut out some unprofitable revenues. The company expects to maintain ca. 30% market share in the next quarters.
- Management does not anticipate deleting AdA 2.0.
- Good result in own brands 4Q23 is, among other things, a result of contract manufacturing, Neuca wants to enter more strongly into generics, among other things, it wants to register an equivalent of Xarelto.
- Neuca estimates the direct impact of the minimum wage increase at around PLN 10.5m annually. In addition, indirectly in supply chain outsourcing services - about PLN 14.5m. In total, about PLN 25m.

- Buyback still planned for 2Q24.
- Capex ca. PLN 100m more or less at the level of depreciation and amortization
- The company does not rule out further M&A in the clinical research area.

**Opinion:** Neutral. The company partially explained margins decline in 4Q23, we believe that the market saw an increased competition after increase in wholesale margin in November. Weak market in CRO business seems to be a right moment to consolidate the market, Neuca decreased its net debt/EBITDA recently and ahead of expected results improvement has a room for investments. We note company mentioned launching Xarelto generic (same drug as Celon Pharma) meaning it plans to expand in prescription generics.

Łukasz Kosiarski, +48 882 108 382

#### KRKA - Krka proposed EUR 7.5 per share as a cash dividend for 2024, up 13.6% y/y

Krka published the cash dividend proposal for 2024. The company intends to payout EUR 7.5 gross per share, up 13.6% vs. 2023 payment. The amount bears 5.8% gross yield on yesterday's close. AGM is scheduled for 11th July.

**Opinion. Positive to neutral.** This is decent boost over EUR 6.6 per share from 2023. The amount is above our EUR 7.2 target and above consensus at EUR 7.0 per share. Nevertheless, the stock price is up 16% YTD and net yield (4.35%) is not so appalling at the moment, although it is also not too small. Krka is among top dividend players in the broad Ex-YU region. Over the last 20 years it was rising annual cash dividend payments by 15% in average (y/y).

Vladan Pavlovic, +381 65 25 15 979

Figure 6. Krka annual DPS in EUR with gross yield and total distribution yield

Source: Company, IPOPEMA Research

### **REAL ESTATE**

### LOKUM DEWELOPER - Pre-sales in 1Q24 decreased by 55% y/y, deliveries up by 30% y/y

Pre-sales came in at 70 units in 1Q24 (vs. 156 units in 1Q23; -55% y/y and -53% q/q). Deliveries amounted to 138 units in 1Q24 (vs. 106 units in 1Q23; +30% y/y). The company informed that dwelling offer arrived at 372 units as of end-1Q24 in comparison with 361 units as of end-4Q23 (+3% Q/Q) and 591 units as of end-1Q23 (-37% y/y). Lokum Deweloper has 584 units under construction.

Opinion: The data regarding pre-sales seem negative, as they indicate a robust drop in volumes in y/y and m/m terms, partially driven by significantly lower offer. As a reminder, the CEO stated during recent conference call that he assumes that the developer may pre-sell only 350 units in 2024E.

In the case of deliveries, the company reported a 30% increase in y/y terms to 138 apartments (in line with our expectations), which in our opinion indicates a solid growth in net profit in 1Q24E. Concurrently, we assume that in coming quarters LKD will report lower deliveries, driven by an uninspiring pipeline.

Figure 7. Lokum Deweloper - quarterly data (units)

|            | 1Q23 | 2Q23 | 3Q23 | 4Q23 | 1Q24 | change | (units) | chang | e (%) |
|------------|------|------|------|------|------|--------|---------|-------|-------|
|            |      |      |      |      |      | y/y    | q/q     | y/y   | q/q   |
| Pre-sales  | 156  | 206  | 196  | 148  | 70   | -86    | -78     | -55%  | -53%  |
| Deliveries | 106  | 125  | 135  | 408  | 138  | 32     | -270    | 30%   | -66%  |
| Offer      | 591  | 522  | 496  | 363  | 372  | -219   | 9       | -37%  | 2%    |

Source: Company, IPOPEMA Research

Figure 8. Lokum - quarterly pre-sales (units)





Figure 9. Lokum – quarterly deliveries (units)



Source: Company, IPOPEMA Research

### **INDUSTRIALS**

### ARCTIC PAPER - Published 4Q23 results

Arctic Paper published its 4Q2023 final results on 04 April 2024 in line with preliminary.

Figure 10. Arctic Paper 4Q23 results

| ATC PW PLN m                           | 1Q21   | 2Q21    | 3Q21   | 4Q21   | 1Q22   | 2Q22   | 3Q22            | 4Q22    | 1Q23   | 2Q23   | 3Q23   | 4Q23   | y/y           | q/q          | 4Q23<br>Prel. | % diff. |
|--|--------|---------|--------|--------|--------|--------|-----------------|---------|--------|--------|--------|--------|---------------|--------------|---------------|---------|
| Revenues                               | 782.8  | 786.6   | 889.7  | 953.5  | 1110.8 | 1296.3 | 1402.1          | 1085.1  | 1032.2 | 836.3  | 854.8  | 825.8  | <i>-23.9%</i> | -3.4%        | 825.9         | 0.00%   |
| Paper segment                          | 547    | 527     | 645    | 689    | 820    | 949    | 1 042.1         | 771     | 722.6  | 566.7  | 590.3  | 580.8  | -24.7%        | -1.6%        |               |         |
| Cellulose segment                      | 243.5  | 265.1   | 255.3  | 272.5  | 291.2  | 347.7  | 360             | 315.5   | 312.9  | 269.6  | 264.5  | 241.7  | -23.4%        | -8.6%        |               |         |
| Consolidation excl.                    | -7.7   | -5.5    | -10.7  | -8     | -0.4   | -0.5   | 0               | -1.5    | -3.2   | 0      | 0.0    | -3.3   |               |              |               |         |
| COGS                                   | -630.5 | -615.8  | -707.2 | -751.2 | -810.1 | -841.2 | -987.4          | -844.8  | -762.9 | -694.6 | -661.6 | -684.5 |               |              |               |         |
| Gross profit                           | 152.3  | 170.8   | 182.5  | 202.3  | 300.6  | 455.1  | 414.7           | 240.3   | 269.4  | 141.6  | 193.2  | 141.5  | -41.1%        | -26.8%       |               |         |
| Gross margin                           | 19.50% | 21.70%. | 20.50% | 21.20% | 27.10% | 35.10% | 29.60%.         | 22.10%. | 26.10% | 16.90% | 0.2    | 0.2    |               |              |               |         |
| EBIT                                   | 43.2   | 54.5    | 72.8   | 74.1   | 176.1  | 298.1  | 259.6           | 109.3   | 155.6  | 39.3   | 95.0   | 67.2   | -38.6%        | -29.3%       | 67.1          | 0.12%   |
| EBIT margin                            | 5.52%  | 6.93%   | 8.18%  | 7.77%  | 15.85% | 23.00% | 18.52%          | 10.07%  | 15.07% | 4.70%  | 0.1    | 0.1    |               |              |               |         |
| Depreciation                           | 29.1   | 29.6    | 29.3   | 26.6   | 29.6   | 32     | 38.7            | 30.7    | 29.9   | 29.6   | 29.5   | 29.3   |               |              |               |         |
| EBITDA                                 | 72.2   | 84.2    | 102.1  | 100.7  | 205.7  | 330.1  | 298.2           | 140     | 185.5  | 68.9   | 124.5  | 96.4   | -31.1%        | -22.6%       | 96.3          | 0.08%   |
| EBITDA margin                          | 9.20%  | 10.70%  | 11.50% | 10.60% | 18.50% | 25.50% | 21.30%          | 12.90%  | 18.00% | 8.20%  | 0.1    | 0.1    |               |              |               |         |
| Income Before Taxes                    | 38.9   | 46.2    | 66.1   | 71.9   | 172    | 301.7  | 342.3           | 111.5   | 154.5  | 51.3   | 83.9   | 51.3   |               |              |               |         |
| Income Tax                             | -6.6   | -10.6   | -12.7  | -17.3  | -25.7  | -47.6  | -60.8           | -36.7   | -22.8  | -4.4   | 25.6   | 15.7   |               |              |               |         |
| %                                      | 17.00% | 22.90%  | 19.20% | 24.00% | 14.90% | 15.80% | <i>17.80%</i> . | 32.90%  | 14.80% | 8.70%  | 0.3    | 0.3    |               |              |               |         |
| Net Income attr. to Parent's s/holders | 29.1   | 18.4    | 36.8   | 42.8   | 120.7  | 215.9  | 221.9           | 72.6    | 107.9  | 39.8   | 51.5   | 47.9   | <i>-34.0%</i> | <i>-7.0%</i> | 47.9          | 0.00%   |
| Net margin                             | 3.70%  | 2.30%   | 4.10%  | 4.50%  | 10.90% | 16.70% | 15.80%          | 6.70%   | 10.50% | 4.80%  | 0.1    | 0.1    |               |              |               |         |
| OCF                                    | 24.1   | 30.6    | 50.6   | 132.9  | 17.9   | 218.3  | 245.1           | 126     | 62.5   | 99.473 | 183.2  | 126.1  |               |              |               |         |

Source: Company, IPOPEMA Research

### GRUPA KETY - New shares registered by KDPW

Grupa Kety informed on 4 April 2024 that the Central Securities Depository of Poland (KDPW) registered 32,124 new shares that were issued as a part of Management's incentive program (based on previously granted subscription warrants). Total number of KTY's shares increased to 9,682,276 shares (vs. 9,650,152 shares prior).

### Messer Tehnogas – Tehnogas reports strong non-consolidated numbers for 2023

Messer Tehnogas, Serbia based technical gases producer, reported strong FY 2023 non-consolidated figures – reports appeared available at APR with no prior announcement. The company managed to boost annual net profit by 32% to RSD 2.7bn due to higher sales and

improved profitability. Annual sales came in at RSD 16bn, up 36% y/y due to much bigger volumes from metallurgy sector (RTB Bor activation of new facility) and probably elevated prices played a role. Operating profit arrived at RSD 3.6bn, up 52% y/y. This surge arrives on the back of higher sales and operating margin expansion of 280bp.

Opinion. Neutral. With ongoing tender offer for minorities, which is likely to be successful, this has no importance, unless most of them decide not to sell shares after observing reported numbers (it is not impossible but seems unlikely given the liquidity, poor corporate governance and uninspiring dividend policy). Reported figures do not include operations in Slovenia, Bosnia and Albania and consolidated figures will differed a lot but we assume the direction and magnitude of change vs. 2023 will be the same as for unconsolidated level. We expect consolidated report to be published by the end of this month.

Vladan Pavlovic, +381 65 25 15 979

Figure 11. Messer Tehnogas annual consolidated figures summary in RSD m

|                                | 2018   | 2019   | 2020   | 2021   | 2022   | 2023*  | 2023E  |
|--------------------------------|--------|--------|--------|--------|--------|--------|--------|
| Sales                          | 10,512 | 12,450 | 13,082 | 15,208 | 16,968 | 16,026 | 22,464 |
| Operating costs                | 8,201  | 9,781  | 10,139 | 11,483 | 13,672 | 12,339 | 17,884 |
| EBITDA                         | 3,420  | 4,060  | 4,459  | 5,184  | 4,910  | 5,043  | 6,435  |
| Depreciation                   | 1,110  | 1,392  | 1,516  | 1,458  | 1,614  | 1,356  | 1,854  |
| EBIT                           | 2,311  | 2,669  | 2,943  | 3,726  | 3,295  | 3,687  | 4,581  |
| Net financial and other result | 74     | 16     | -142   | 19     | -543   | -566   | -1,000 |
| Pre-tax profit                 | 2,385  | 2,684  | 2,801  | 3,745  | 2,753  | 3,121  | 3,581  |
| Tax                            | -272   | -368   | -408   | -529   | -453   | -484   | -537   |
| Minorities                     | 0      | -2     | -2     | -2     | -4     | 0      | -2     |
| Net income                     | 2,113  | 2,314  | 2,391  | 3,214  | 2,295  | 2,637  | 3,042  |

Source: Company, IPOPEMA Research, \*non-consolidated (only parent company in Serbia)

### **TRAVEL & LEISURE**

#### AIRCRAFT SERVICES - Ryan Air and Wizz Air monthly data

Ryan Air informed that number of passengers in March arrived at 13.6m (+8% y/y and +23% m/m). Load factor stood at 93% (flattish y/y; +1p.p. m/m). Regarding Wizz Air, the numbers arrived at 4.8m (+12% y/y, +9% m/m) and 91% (-1pp. y/y), respectively.

Figure 12. Ryan Air and Wizz Air - operational data

|                 | Mar'23 | Feb'24 | Mar'24 | change m/m | change y/y |
|-----------------|--------|--------|--------|------------|------------|
| Traffic (m)     |        |        |        |            |            |
| Ryan Air        | 12.6   | 11.1   | 13.6   | 23%        | 8%         |
| Wizz Air        | 4.3    | 4.4    | 4.8    | 9%         | 12%        |
| Load factor (%) |        |        |        |            |            |
| Ryan Air        | 93%    | 92%    | 93%    | 1%         | 0%         |
| Wizz Air        | 92%    | 90%    | 91%    | 1%         | -1%        |

Source: Company, IPOPEMA Research

#### RAINBOW TOURS - 4Q23 preliminary consolidated net profit amounted to PLN 4.8m

The group informed that its 4Q23 preliminary consolidated revenues amounted to PLN 594.3m, EBITDA stood at PLN 10.3m and a net profit came in at PLN 4.8m.

Figure 13. Rainbow Tours – 4Q23 preliminary consolidated results (PLNm)

|               | 1Q22  | 2Q22  | 3Q22    | 4Q22  | 1Q23  | 2Q23  | 3Q23    | 4Q23A | Y/Y   | Q/Q    |
|---------------|-------|-------|---------|-------|-------|-------|---------|-------|-------|--------|
| Revenues      | 315.8 | 504.7 | 1,113.1 | 459.8 | 556.0 | 709.1 | 1,434.0 | 594.3 | 29.3% | -58.6% |
| EBITDA        | -1.3  | 1.4   | 68.8    | -14.5 | 30.6  | 49.6  | 146.4   | 10.3  | n.a.  | -93.0% |
| Net profit    | -7.8  | -5.0  | 54.8    | -19.6 | 18.8  | 34.1  | 116.0   | 4.8   | n.a.  | -95.8% |
|               |       |       |         |       |       |       |         |       |       |        |
| EBITDA margin | -0.4% | 0.3%  | 6.2%    | -3.2% | 5.5%  | 7.0%  | 10.2%   | 1.7%  |       |        |
| Net margin    | -2.5% | -1.0% | 4.9%    | -4.3% | 3.4%  | 4.8%  | 8.1%    | 0.8%  |       |        |

Source: Company, IPOPEMA Research

**Opinion: Mixed.** On the one hand the group reported strong improvement in financial results in y/y terms, which are above our original forecasts, where we predicted EBITDA of PLN 7.3m and net profit of PLN 2.8m. On the other hand, after the publication of standalone preliminary results, we upgraded our expectations of consolidated net profit to PLN 12.0m. We suppose that consolidated 4Q23A numbers were strongly affected by a loss in hospitality segment (we do not exclude the impact of consolidation adjustments).

Adrian Górniak, +48 514 995 073

#### **OTHERS**

#### DELKO - EGM scheduled on 8 May 2024

Delko is going to hold an EGM on 8 May 2024 in order to vote changes in supervisory board.


#### **MACRO NEWS**

#### POLAND - Uncertain inflation outlook still key for MPC

Polish Monetary Policy Council left interest rates unchanged with the main rate still at 5.75%. The decision was in line with our forecast and broad consensus.


Today at 15:00CET NBP governor will hold his regular post-meeting conference. We do not expect this event to provide any breaking information that could affect monetary policy outlook in Poland.

Figure 14. BANKS - NIM vs Base rate (%)




Source: NBP, IPOPEMA Research

Figure 15. BANKS - PL mortgage growth (%, y/y)



Source: Company, IPOPEMA Research

Figure 16. Monthly pre-sales (k units)



Source: Otodom, JLL, IPOPEMA Research

Figure 17. Quarterly pre-sales (k units) vs. main rate (%)



Source: JLL, NBP, BIK, IPOPEMA Research

Opinion Macro. The tone of the post-meeting statement did not change significantly compared to the previous months. The MPC again underlined elevated uncertainty how inflation rate will evolve in 2H24 owing to likely at least partly unfreeze of energy prices for households, wage hikes in public sector, high wages growth rate in corporate sector and reviving consumers demand. Overall, we sustain our call that there will be no rate cuts this year in Poland. The consensus is converging gradually to our view.

Opinion Banks. Slightly Positive, however expected. The MPC decision supports our investment thesis, interest rates higher for longer. Rates freeze will have a positive impact on NIM, especially

that banks have been lowering deposit rates in recent months at a higher pace than the asset yield declined. At the same time higher rates for longer may have somewhat adverse impact on lending volumes and risk costs. Still the assets quality remains buoyant, while coverage has been improving. While the volume outlook looks promising, with retail volumes, especially mortgages in 1H24E to be supported by the pipeline of the motions concerning the recent ceased state-subsidised mortgage program rolled by the previous government (some 50k remaining), while the 2H24 will be supported by the recently announced new government subsidised-mortgage program (50k), expected to be in place in 3Q24. At the same time, we expect corporate segment volumes to pick up in 2H24, with EU funds flow from recently preannounced EC two decisions to unlock up to EUR137bn for Poland from the RRF and cohesion funds.

Thus, overall, we believe that the rate freeze should have mildly positive impact on the banking sector consensus estimates for 2024 and beyond, as consensus has been converging towards our estimates of flattish rates in 2024, allowing banks to report stronger ROEs. Sector data for Jan-Feb'24 shows record high NII of PLN 17.02bn, with NIM at 3.86% (-2bps y/y). Although, YTD ROE is slightly weaker at 16.8% vs. 17.5% in 2023, but capital is growing strongly due to higher profitability and positive bond valuation. Stronger ROEs should be visible in June-July, once dividends incl. extraordinary once, will be paid out.

Banks with highest bottom-line sensitivity to interest rates, which should benefit most from yesterday's decision, include Bank Millennium, Bank Handlowy, Alior Bank and longer-term PKO BP. On the other hand we see ING BSK and BNP Paribas Polska as least sensitive in such comparison.

**Opinion Real Estate.** MPC's decision was in line with our (and market) expectations and does not change our view on the sector. February Otodom's data indicate that the number of presold dwellings increased one more time in y/y terms (+10% y/y) and were flattish in comparison with January. We point to solid reading regarding submitted mortgage motions, which in February grew by 40% y/y and by 18% m/m (and are above pre-BK2% program era).

We point to announced other governmental program, "Mieszkanie na start", which is going to be probably started in 3Q24E. Thus, we predict that it will support the pre-sales in 2H24E. Concurrently, we note that in 1Q24E the banks will convert "Bezpieczny kredyt" motions (nearly 50k) into final mortgage agreements, which will additionally underpin 1H24E volumes.

The market offer is still lower y/y (-7% y/y), yet the developers have started to expand their offers (especially the biggest companies, such as ARH, MUR, 1AT or DVL), which is also reflected in Statistics Poland and Otodom data. On the other hand, smaller developers may still have problems with new commencements, as the financing costs are still too high for them. Thus, we keep our base case scenario for a gradual offer recovery in coming months.

We firmly believe that companies such as DOM, 1AT, DVL or ARH will be the beneficiaries of a positive market environment and are likely to report solid margins in coming quarters, underpinned by dwelling price hikes (we predict single-digit increases in 2024E, vs. double-digit hikes in 2023E; as of now, both, Otodom and rynekpierwotny.pl data do not indicate any drop in prices in m/m terms) and a favourable cost-side trends months (we note that rebar prices are ca. 20% lower in y/y terms; moreover, PSB data indicate that the average basket of main materials is also cheaper in comparison with 2023 numbers).

Marcin Sulewski, CFA, +48 889 695 633, Marta Czajkowska-Bałdyga +48 509 318 601, Adrian Górniak +48 514 995 073

#### ROMANIA - Rates stable but first cut looming

The Board of the National Bank of Romania left interest rates unchanged with the policy rate still at 7%. The decision was in line with our expectations and broad market consensus.

In the post-meeting statement, the Board noticed that last available economic data suggest stronger-than-expected GDP growth in 1Q24 yet slower in y/y terms than in 3% recorded in the last quarter of 2023. Retail sales growth rate improved while industrial and construction output contracted at a higher pace.

Rate setters expect the disinflation process to continue at a slower pace than shown in February's Inflation Report. Also, the statement again underlined uncertainty of what will be the effect of fiscal policy (wages and pension increases).

Overall, the post-meeting statement did not provide any guidance what could be the next decisions. However, relying on the central bank's governor comment from mid-February and expected inflation developments we expect first rate cut to take place in May.

**Opinion Macro.** In mid-February, governor Mugur Isarescu said that inflation needs to fall in two consecutive months after the January's tax-induced spike before the Board decides to cut interest rates. This condition should be met this month and in May the rate setters will have updated CPI and GDP forecasts. Thus, next meeting scheduled for May 13 looks to be a likely moment for the first 25bp rate cut, in our view. We expect that once started, the easing cycle will proceed in 25bp/meeting steps.

Opinion on Romanian banks: Neutral. We did not expect any changes in the policy interest rates. This decision does not come as a surprise, as it does not affect the current demand dynamics for credit in terms of the retail and corporate segments. Considering this decision, we do not expect demand to be stimulated or depressed as a consequence. Therefore, we keep our expectations in terms of growth in loan volumes unchanged. Moreover, we expect the top line and bottom line results for Banca Transilvania and BRD – GSG to stay at elevated levels during 1H 2024, followed by a decrease in 2H2024.

Marcin Sulewski, CFA, +48 889 695 633, Ionut Gavris +48 514 995 141

# PAIR TRADE SUMMARY

| Beginning  | Fadina Data | Long           |        |                | hort   |        | Total return |        | Chahua |
|------------|-------------|----------------|--------|----------------|--------|--------|--------------|--------|--------|
| Date       | Ending Date | LO             | ng     | 3              | nort   | Long   | Short        | Total  | Status |
| 2023-10-26 |             | PKO BP         | PKO PW | PZU            | PZU PW | 47.1%  | -6.1%        | 41.0%  | Open   |
| 2023-10-26 |             | mBank          | MBK PW | Millennium     | MIL PW | 43.4%  | -45.4%       | -2.0%  | Open   |
| 2023-10-26 |             | CEZ AS         | CEZ PW | PGE            | PGE PW | -22.2% | -5.4%        | -27.6% | Open   |
| 2023-10-26 |             | CEZ AS         | CEZ PW | Tauron         | TPE PW | -22.2% | 17.2%        | -5.0%  | Open   |
| 2023-10-26 |             | CEZ AS         | CEZ PW | ENEA           | ENE PW | -22.2% | -37.9%       | -60.1% | Open   |
| 2023-10-26 |             | MOL            | MOL HB | OMV Petrom     | SNP RO | 5.3%   | -21.9%       | -16.5% | Open   |
| 2023-04-01 |             | Playway        | PLW PW | PCF Group      | PCF PW | -27.2% | 45.0%        | 17.8%  | Open   |
| 2022-11-02 | 2024-03-28  | LPP            | LPP PW | CCC            | CCC PW | 90.8%  | -91.7%       | -0.8%  | Closed |
| 2023-12-01 | 2024-02-28  | Orange Polska  | OPL PW | Cyfrowy Polsat | CPS PW | 5.4%   | 4.5%         | 9.9%   | Closed |
| 2023-08-01 | 2023-12-01  | Amica          | AMC PW | Forte          | FTE PW | -10.2% | 10.5%        | 0.3%   | Closed |
| 2023-10-02 | 2023-11-02  | Cyfrowy Polsat | CPS PW | Orange Polska  | OPL PW | 13.9%  | -8.3%        | 5.6%   | Closed |
| 2022-12-01 | 2023-09-07  | Orange Polska  | OPL PW | Cyfrowy Polsat | CPS PW | 15.7%  | 26.7%        | 42.4%  | Closed |
| 2023-07-04 | 2023-08-31  | Millenium      | MIL PW | PZU            | PZU PW | 5.3%   | -4.1%        | 1.3%   | Closed |
| 2023-07-04 | 2023-08-31  | mBank          | MBK PW | PZU            | PZU PW | 5.7%   | -4.1%        | 1.6%   | Closed |
| 2023-07-04 | 2023-08-31  | PGE            | PGE PW | CEZ            | CEZ CP | 16.0%  | -5.3%        | 10.7%  | Closed |
| 2023-07-04 | 2023-08-31  | Tauron         | TPE PW | CEZ            | CEZ CP | 53.1%  | -5.3%        | 47.7%  | Closed |
| 2023-07-04 | 2023-08-31  | Enea           | ENA PW | CEZ            | CEZ CP | 33.3%  | -5.3%        | 27.9%  | Closed |
| 2022-08-01 | 2023-05-31  | Allegro        | ALE PW | CCC            | CCC PW | 41.8%  | -5.0%        | 36.9%  | Closed |
| 2023-04-01 | 2023-05-02  | PKO BP         | PKO PW | Pekao          | PEO PW | 11.8%  | -11.5%       | 0.3%   | Closed |

NOTE: We calculate total return based on first opening prices after publishing pair trade and include FX effect.

# **SHORT POSITIONS**

|           | # of institutions | % of capital | daily change | x30 ADV |
|-----------|-------------------|--------------|--------------|---------|
| ALLEGRO   | 2                 | 1.01%        | =            | 2.9     |
| BUDIMEX   | 1                 | 0.50%        | =            | 1.9     |
| CDPROJEKT | 3                 | 2.30%        | UP           | 3.9     |
| DINOPL    | 1                 | 0.50%        | =            | 2.6     |
| JSW       | 1                 | 0.80%        | =            | 1.9     |
| LPP       | 1                 | 0.81%        | =            | 3.4     |
| PEPCO     | 1                 | 0.52%        | =            | 1.5     |

<sup>\*</sup> sum of single short positions of at least 0.5% of capital

## **RECOMMENDATIONS' SUMMARY & COVERAGE MULTIPLES**

| _  | Recomm-   | Fair Value   | Upside /  | Current   | Perforn  | nance  | Market Cap   | P/E  |   | P/BV  |  | DY   |   |
|--|---|--|---|---|--|--|--|--|---|---|--|--|---|
| Company  | endation  | (Local)  | downside  | Price (Local)   | 1D   | YTD  | in EUR m   | 2024E  | 2025E   | 2024E   | 2025E  | 2024E  | 2025E   |
| BANKS  |   |  |   |   |  |  | MEDIAN   | 9.1  | 8.4   | 1.6   | 1.4  | 7.0%   | 8.0%  |
| ALIOR  | BUY   | 97.60  | 28%   | 102.15  | 3.3%   | 33.8%  | 3,108.0  | 7.0  | 7.1   | 1.3   | 1.1  | 4.6%   | 4.3%  |
| BANCA TRANSILVANIA   | HOLD  | 21.80  | -22%  | 28.00   | 0.0%   | 15.4%  | 3,987.9  | 6.8  | 6.2   | 1.5   | 1.3  | 7.3%   | 13.0%   |
| BNP PARIBAS BANK POLSKA<br>BRD-GSG   | BUY<br>HOLD   | 69.50<br>16.50   | -37%<br>-24%  | 110.00<br>21.75   | 1.9%<br>-1.1%  | 28.5%<br>27.8%   | 3,779.2  | 14.4<br>9.1  | 11.3<br>7.9   | 1.2   | 1.1  | 0.0%<br>7.4%   | 1.7%<br>10.2%   |
| HANDLOWY   | HOLD  | 91.80  | -24%<br>-19%  | 113.00  | 0.7%   | 11.4%  | 3,050.7<br>3,440.9   | 7.9  | 7.9<br>10.3   | 1.5<br>1.7  | 1.4<br>1.7   | 10.3%  | 12.6%   |
| ING BSK  | BUY   | 213.40   | -19%  | 340.00  | -2.2%  | 32.8%  | 10,308.8   | 12.7   | 12.4  | 3.1   | 2.8  | 3.7%   | 3.9%  |
| KOMERCNI BANKA   | U/R   | 213.40   | 37.10   | 855.00  | 0.6%   | 18.0%  | 6,375.7  | na   | 10.2  | 1.3   | 1.2  | 9.5%   | 7.6%  |
| MBANK  | BUY   | 637.90   | -13%  | 731.60  | 0.1%   | 36.7%  | 7,314.0  | 9.6  | 8.1   | 2.3   | 2.1  | 0.0%   | 5.2%  |
| MILLENNIUM   | BUY   | 8.65   | -19%  | 10.67   | 2.8%   | 27.7%  | 3,016.6  | 10.5   | 8.6   | 1.8   | 1.4  | 0.0%   | 0.0%  |
| MONETA   | U/R   |  |   | 101.40  | 0.4%   | 8.3%   | 2,045.9  | 9.8  | 9.4   | 1.6   | 1.5  | 8.7%   | 9.1%  |
| NLB BANKA  | BUY   | 138.00   | 27%   | 109.00  | -0.9%  | 28.2%  | 2,180.0  | 4.7  | 4.8   | 0.7   | 0.6  | 10.1%  | 10.1%   |
| PEKAO  | BUY   | 183.50   | 0%  | 184.10  | 1.5%   | 21.1%  | 11,261.2   | 8.5  | 8.3   | 1.5   | 1.5  | 10.1%  | 8.9%  |
| PKO BP   | BUY   | 60.00  | 0%  | 60.00   | 1.4%   | 22.4%  | 17,478.9   | 8.9  | 8.5   | 1.6   | 1.5  | 5.3%   | 8.4%  |
| SANTANDER BANK PL<br>FINANCIALS  | BUY   | 611.60   | 6%  | 576.00  | 0.6%   | 17.6%  | 13,717.6<br>MEDIAN   | 9.8<br><b>11.9</b>   | 8.1<br>11.1   | 1.7<br><b>3.6</b>   | 1.5<br>3.2   | 6.6%   | 7.7%  |
| BUCHAREST STOCK EXCHANGE   | BUY   | 86.00  | 32%   | 65.00   | 0.9%   | -0.9%  | 105.3  | 15.2   | 10.9  | 7.6   | 9.7  | 3.9%   | <b>7.1%</b><br>4.5%   |
| GPW  | U/R   | 80.00  | 3270  | 42.05   | 0.4%   | -1.1%  | 411.3  | na   | 11.1  | 1.6   | 1.6  | 6.8%   | 7.1%  |
| KRUK   | U/R   |  |   | 450.00  | 6.4%   | -5.7%  | 2.026.0  | na   | na  | na  | na   | na   | na  |
| PZU  | BUY   | 41.30  | -17%  | 49.62   | 1.6%   | 5.0%   | 9,985.8  | 10.6   | 11.3  | 1.9   | 1.8  | 5.3%   | 6.6%  |
| QUERCUS  | U/R   |  |   | 6.66  | -0.3%  | 14.8%  | 85.6   | 13.3   | 13.3  | 3.7   | 3.7  | 7.5%   | 7.5%  |
| XTB  | U/R   |  |   | 57.76   | 2.2%   | 52.7%  | 1,580.1  | 8.5  | 7.9   | 3.6   | 3.2  | 8.4%   | 8.4%  |
| HOLDING COMPANIES  |   |  |   |   |  |  | MEDIAN   | 14.6   | 14.0  | 0.7   | 0.7  | 3.9%   | 3.9%  |
| ADRIS GRUPA  | HOLD  | 52.80  | -13%  | 61.00   | 0.3%   | 7.8%   | 955.2  | 14.6   | 14.0  | 0.7   | 0.7  | 3.9%   | 3.9%  |
| FONDUL PROPRIETATEA  | U/R   |  |   | 0.52  | 0.9%   | -0.4%  | 600.8  | na   | na  | na  | na   | na   | na  |
| REAL ESTATE  |   |  |   |   |  |  | MEDIAN   | 11.5   | 9.3   | 1.3   | 1.2  | 7.3%   | 5.7%  |
| ATAL   | BUY   | 71.00  | 18%   | 60.00   | 0.0%   | 7.1%   | 604.3  | 9.6  | 8.1   | 1.7   | 1.6  | 8.4%   | 8.3%  |
| ARCHICOM   | BUY   | 37.20  | 16%   | 32.00   | -2.4%  | 17.5%  | 436.2  | 29.3   | 7.7   | 1.5   | 1.3  | 6.8%   | 3.4%  |
| DEVELIA  | BUY   | 6.16   | 0%  | 6.15  | 0.3%   | 35.5%  | 641.5  | 9.9  | 8.8   | 2.0   | 1.8  | 7.9%   | 7.6%  |
| DOM DEVELOPMENT  | BUY   | 177.50   | -3%   | 182.40  | 1.9%   | 22.1%  | 1,092.4  | 9.9  | 9.3   | 3.5   | 3.1  | 6.3%   | 6.6%  |
| ECHO INVESTMENT<br>GTC   | U/R   | 5.96   | 10%   | 4.72<br>5.42  | 0.2%<br>-4.6%  | 18.0%<br>28.1%   | 454.0<br>725.4   | 39.3<br>9.5  | 11.4<br>9.3   | 1.0<br>0.7  | 0.9  | 10.6%<br>5.5%  | 7.9%<br>6.1%  |
| IMPACT DEV. & CONTRACTOR   | BUY<br>BUY  | 0.32   | 32%   | 0.24  | 0.4%   | -7.2%  | 116.2  | 68.5   | 55.4  | 1.1   | 0.6<br>1.1   | 1.5%   | 1.8%  |
| LOKUM DEWELOPER  | HOLD  | 24.20  | -17%  | 29.20   | 8.1%   | 15.0%  | 122.5  | 13.0   | 9.9   | 1.1   | 1.0  | 8.3%   | 3.8%  |
| MARVIPOL DEVELOPMENT   | BUY   | 11.15  | 24%   | 9.00  | 0.9%   | 16.3%  | 87.4   | 9.3  | 6.8   | 0.5   | 0.5  | 11.8%  | 5.4%  |
| ONE UNITED PROPERTIES  | BUY   | 1.27   | 26%   | 1.00  | 2.4%   | 2.6%   | 748.2  | 97.9   | 115.8   | 11.5  | 11.7   | 1.0%   | 0.9%  |
| Company  | Recomm-   | Fair Value   | Upside /  | Current   | Perforn  | nance  | Market Cap   | P/E  |   | EV/EBITDA   |  | DY   |   |
|  | endation  | (Local)  | downside  | Price (Local)   | 1D   | YTD  | in EUR m   | 2024E  | 2025E   | 2024E   | 2025E  | 2024E  | 2025E   |
| AGRICULTURE  |   |  |   |   |  |  | MEDIAN   | na   | na  | na  | na   | na   | na  |
| ASTARTA<br>KERNEL  | U/R   |  |   | 29.00   | -1.4%  | 1.0%   | 169.0  | na   | na  | na  | na   | na   | na  |
|  | 11.00   |  |   |   |  |  |  |  |   |   |  |  |   |
|  | U/R   |  |   | 9.20  | 3.5%   | 0.5%   | 643.3  | na   | na  | na  | na   | na   | na  |
| BIOTECH & HEALTHCARE   |   | 45.50  | 40/   | 9.20  | 3.5%   | 0.5%   | 643.3<br>MEDIAN  | na<br><b>22.0</b>  | na<br><b>13.2</b>   | na<br><b>8.2</b>  | na<br><b>8.2</b>   | na<br><b>0.0%</b>  | na<br><b>0.4%</b>   |
| BIOTECH & HEALTHCARE CELON PHARMA  | HOLD  | 15.50  | 1%  | 9.20  | 3.5%<br>1.2%   | -0.5%  | 643.3<br>MEDIAN<br>184.4   | na<br><b>22.0</b><br>26.8  | na<br>13.2<br>14.0  | 8.2<br>8.2  | na<br><b>8.2</b><br>6.3  | 0.0%<br>0.6%   | 0.4%<br>0.6%  |
| BIOTECH & HEALTHCARE<br>CELON PHARMA<br>KRKA   | HOLD<br>HOLD  | 111.00   | -13%  | 9.20<br>15.38<br>127.50   | 3.5%<br>1.2%<br>0.0%   | -0.5%<br>15.9%   | 643.3<br><b>MEDIAN</b><br>184.4<br>4,182.0   | na<br><b>22.0</b><br>26.8<br>12.6  | 13.2<br>14.0<br>12.5  | 8.2<br>8.2<br>7.9   | na<br><b>8.2</b><br>6.3<br>8.1   | na<br><b>0.0%</b><br>0.6%<br>5.2%  | 0.4%<br>0.6%<br>5.6%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS   | HOLD<br>HOLD<br>BUY   | 111.00<br>41.20  | -13%<br>58%   | 9.20<br>15.38<br>127.50<br>26.00  | 3.5%<br>1.2%<br>0.0%<br>-3.1%  | -0.5%<br>15.9%<br>-14.9%   | 643.3<br><b>MEDIAN</b><br>184.4<br>4,182.0<br>60.3   | 22.0<br>26.8<br>12.6<br>na   | 13.2<br>14.0<br>12.5<br>na  | 8.2<br>8.2<br>7.9<br>na   | 8.2<br>6.3<br>8.1<br>126.0   | 0.0%<br>0.6%<br>5.2%<br>0.0%   | 0.4%<br>0.6%<br>5.6%<br>0.0%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE   | HOLD<br>HOLD<br>BUY<br>BUY                                    | 111.00<br>41.20<br>5.64  | -13%<br>58%<br>33%  | 9.20<br>15.38<br>127.50<br>26.00<br>4.24  | 1.2%<br>0.0%<br>-3.1%<br>3.8%  | -0.5%<br>15.9%<br>-14.9%<br>6.5%   | 643.3<br>MEDIAN<br>184.4<br>4,182.0<br>60.3<br>113.4   | 22.0<br>26.8<br>12.6<br>na<br>2.8  | 13.2<br>14.0<br>12.5<br>na<br>1.8   | 8.2<br>8.2<br>7.9<br>na<br>3.0  | 8.2<br>6.3<br>8.1<br>126.0<br>2.2  | na<br>0.0%<br>0.6%<br>5.2%<br>0.0%<br>0.1%   | 0.4%<br>0.6%<br>5.6%<br>0.0%<br>0.1%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE  | HOLD<br>HOLD<br>BUY<br>BUY<br>BUY                             | 111.00<br>41.20<br>5.64<br>25.60   | -13%<br>58%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00   | 3.5%<br>1.2%<br>0.0%<br>-3.1%<br>3.8%<br>0.4%  | -0.5%<br>15.9%<br>-14.9%<br>6.5%<br>-12.8%   | 643.3<br>MEDIAN<br>184.4<br>4,182.0<br>60.3<br>113.4<br>66.7   | 22.0<br>26.8<br>12.6<br>na<br>2.8<br>na  | na 13.2 14.0 12.5 na 1.8 na   | 8.2<br>8.2<br>7.9<br>na   | 8.2<br>6.3<br>8.1<br>126.0<br>2.2<br>na  | na<br>0.0%<br>0.6%<br>5.2%<br>0.0%<br>0.1%<br>0.0%   | 0.4%<br>0.6%<br>5.6%<br>0.0%<br>0.1%<br>0.0%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE   | HOLD<br>HOLD<br>BUY<br>BUY                                    | 111.00<br>41.20<br>5.64  | -13%<br>58%<br>33%<br>51%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24  | 1.2%<br>0.0%<br>-3.1%<br>3.8%  | -0.5%<br>15.9%<br>-14.9%<br>6.5%   | 643.3<br>MEDIAN<br>184.4<br>4,182.0<br>60.3<br>113.4   | 22.0<br>26.8<br>12.6<br>na<br>2.8  | 13.2<br>14.0<br>12.5<br>na<br>1.8   | 8.2<br>8.2<br>7.9<br>na<br>3.0<br>na  | 8.2<br>6.3<br>8.1<br>126.0<br>2.2  | na<br>0.0%<br>0.6%<br>5.2%<br>0.0%<br>0.1%   | 0.4%<br>0.6%<br>5.6%<br>0.0%<br>0.1%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG POLTREG POLTREG  | HOLD<br>HOLD<br>BUY<br>BUY<br>BUY<br>BUY                      | 111.00<br>41.20<br>5.64<br>25.60<br>849.00   | -13%<br>58%<br>33%<br>51%<br>-4%  | 9,20<br>15,38<br>127,50<br>26,00<br>4,24<br>17,00<br>885,00   | 3.5%<br>1.2%<br>0.0%<br>-3.1%<br>3.8%<br>0.4%<br>1.4%  | -0.5%<br>15.9%<br>-14.9%<br>6.5%<br>-12.8%<br>-4.3%  | 643.3<br>MEDIAN<br>184.4<br>4,182.0<br>60.3<br>113.4<br>66.7<br>926.8  | 22.0<br>26.8<br>12.6<br>na<br>2.8<br>na<br>18.1  | na<br>13.2<br>14.0<br>12.5<br>na<br>1.8<br>na<br>15.8   | 8.2<br>8.2<br>7.9<br>na<br>3.0<br>na<br>9.5   | 8.2<br>6.3<br>8.1<br>126.0<br>2.2<br>na<br>8.4   | na<br>0.0%<br>0.6%<br>5.2%<br>0.0%<br>0.1%<br>0.0%<br>1.6%   | 0.4%<br>0.6%<br>5.6%<br>0.0%<br>0.1%<br>0.0%<br>1.9%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG  | HOLD<br>HOLD<br>BUY<br>BUY<br>BUY<br>BUY<br>BUY               | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40  | -13%<br>58%<br>33%<br>51%<br>-4%<br>48%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>55.00  | 3.5%<br>1.2%<br>0.0%<br>-3.1%<br>3.8%<br>0.4%<br>1.4%<br>-1.1%   | -0.5%<br>-0.5%<br>15.9%<br>-14.9%<br>6.5%<br>-12.8%<br>-4.3%<br>10.4%  | 643.3<br>MEDIAN<br>184.4<br>4,182.0<br>60.3<br>113.4<br>66.7<br>926.8<br>59.8  | 22.0<br>26.8<br>12.6<br>na<br>2.8<br>na<br>18.1  | na<br>13.2<br>14.0<br>12.5<br>na<br>1.8<br>na<br>15.8   | 8.2<br>8.2<br>7.9<br>na<br>3.0<br>na<br>9.5   | na  8.2  6.3  8.1  126.0  2.2  na  8.4  na   | na<br>0.0%<br>0.6%<br>5.2%<br>0.0%<br>0.1%<br>0.0%<br>1.6%<br>0.0%   | 0.4%<br>0.6%<br>5.6%<br>0.0%<br>0.1%<br>0.0%<br>1.9%<br>0.0%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRIKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA  | HOLD<br>HOLD<br>BUY<br>BUY<br>BUY<br>BUY<br>BUY<br>BUY<br>BUY | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00  | -13%<br>58%<br>33%<br>51%<br>-4%<br>48%<br>82%<br>19%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>55.00<br>54.60<br>194.20<br>69.00  | 3.5%  1.2% 0.0% -3.1% 3.8% 0.4% 1.4% -1.1% 0.0% -1.4% 3.4%   | 0.5%<br>-0.5%<br>15.9%<br>-14.9%<br>6.5%<br>-12.8%<br>-4.3%<br>10.4%<br>-5.0%<br>-0.9%<br>17.9%  | 643.3<br>MEDIAN<br>184.4<br>4,182.0<br>60.3<br>113.4<br>66.7<br>926.8<br>59.8<br>301.7<br>123.4<br>295.2   | na  22.0  26.8  12.6  na  2.8  na  18.1  na  na  64.8  | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 1.2 21.1   | na  8.2  8.2  7.9  na  3.0  na  9.5  na  na  15.8   | na  8.2  6.3  8.1  126.0  2.2  na  8.4  na  na  11.8   | na 0.0% 0.6% 5.2% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0   | 0.496 0.6% 5.6% 0.0% 0.1% 0.0% 1.9% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK  | HOLD HOLD BUY             | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60  | -13%<br>58%<br>33%<br>51%<br>-4%<br>48%<br>82%<br>19%<br>1%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>55.00<br>54.60<br>194.20<br>69.00<br>137.00  | 3.5%  1.2% 0.0% -3.1% 3.8% 0.4% 1.4% -1.1% 0.0% -1.4% 3.4% -2.4%   | 0.5%<br>-0.5%<br>15.9%<br>-14.9%<br>6.5%<br>-12.8%<br>-4.3%<br>10.4%<br>-5.0%<br>-0.9%<br>17.9%<br>63.0%   | 643.3  MEDIAN  184.4 4,182.0 60.3 113.4 66.7 926.8 59.8 301.7 123.4 295.2 272.3  | na  22.0  26.8  12.6  na  2.8  na  18.1  na  64.8  35.0  25.8  | na 13.2 14.0 12.5 na 1.8 na 15.8 na 1.2 21.1 20.6   | na  8.2  8.2  7.9  na  3.0  na  9.5  na  na  15.8   | na  8.2  6.3  8.1  126.0  2.2  na  8.4  na  na  11.8   | na 0.0% 0.6% 5.2% 0.0% 0.1% 0.0% 1.6% 0.0% 0.0% 0.0% 0.0% 1.33%  | 0.4% 0.6% 5.6% 0.0% 0.1% 0.0% 1.9% 0.0% 0.0% 1.5% 0.0%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL  | HOLD<br>HOLD<br>BUY<br>BUY<br>BUY<br>BUY<br>BUY<br>BUY<br>BUY | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00  | -13%<br>58%<br>33%<br>51%<br>-4%<br>48%<br>82%<br>19%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>55.00<br>54.60<br>194.20<br>69.00  | 3.5%  1.2% 0.0% -3.1% 3.8% 0.4% 1.4% -1.1% 0.0% -1.4% 3.4%   | 0.5%<br>-0.5%<br>15.9%<br>-14.9%<br>6.5%<br>-12.8%<br>-4.3%<br>10.4%<br>-5.0%<br>-0.9%<br>17.9%  | 643.3  MEDIAN  184.4 4,182.0 60.3 113.4 66.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  | na <b>22.0</b> 26.8 12.6 na 2.8 na 18.1 na na 54.8 35.0 25.8 11.6  | na 13.2 14.0 12.5 na 1.8 na 15.8 na 12 21.1 20.6 11.3   | na  8.2  8.2  7.9  na  3.0  na  9.5  na  na  15.8  15.8  6.8  | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6   | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  0.0%  3.7%   | 0.496 0.6% 5.696 0.0% 0.196 0.0% 1.996 0.0% 0.0% 0.0% 1.596 0.0% 4.34   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLITREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION  | HOLD HOLD BUY             | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20   | -13%<br>58%<br>33%<br>51%<br>-4%<br>48%<br>82%<br>19%<br>1%<br>-22%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>55.00<br>54.60<br>194.20<br>69.00<br>137.00<br>88.60   | 3.5%  1.2% 0.0% -3.1% 3.8% 0.4% 1.4% -1.1% 0.0% -1.4% 3.4% -2.4% 1.8%  | -0.5%<br>15.9%<br>-14.9%<br>6.5%<br>-12.8%<br>-4.3%<br>10.4%<br>-5.0%<br>-0.9%<br>17.9%<br>63.0%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 66.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  MEDIAN   | na  22.0  26.8  12.6  na  2.8  na  18.1  na  na  64.8  35.0  25.8  11.6  | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 1.2 21.1 20.6 11.3 6.8   | na  8.2  8.2  7.9  na  3.0  na  9.5  na  na  15.8  15.3  6.8  | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6   | na 0.0% 0.6% 5.2% 0.0% 0.1% 0.0% 1.6% 0.0% 0.0% 0.0% 0.0% 3.7% 3.1%  | 0.496 0.6% 5.6% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNLEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO  | HOLD HOLD BUY             | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20   | -13%<br>58%<br>33%<br>51%<br>-4%<br>48%<br>82%<br>19%<br>-22%<br>-19%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>54.60<br>194.20<br>69.00<br>137.00<br>88.60  | 3.5%  1.2% 0.0% -3.19 3.8% 0.4% 1.4% -1.19 3.4% -2.4% 1.8%   | -0.5%<br>-0.5%<br>15.9%<br>-14.9%<br>6.5%<br>-12.8%<br>-4.3%<br>10.4%<br>-5.0%<br>17.9%<br>63.0%<br>12.7%  | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 66.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 16.1  | na  22.0  26.8  12.6  na  2.8  na  18.1  na  na  64.8  35.0  25.8  11.6  8.0   | na 13.2 14.0 12.5 na 1.8 na 15.8 na 12 21.1 20.6 11.3 6.8 7.7   | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  5.0  5.3   | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.9   | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  3.7%  3.1%   | 0.4% 0.6% 5.6% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 1.9% 0.0% 4.5% 6.0%   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD  | HOLD HOLD BUY             | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20   | -13%<br>58%<br>33%<br>51%<br>-4%<br>48%<br>82%<br>19%<br>1%<br>-22%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>55.00<br>54.60<br>194.20<br>69.00<br>137.00<br>88.60   | 3.5%<br>1.2%<br>0.0%<br>-3.1%<br>3.8%<br>0.4%<br>1.4%<br>-1.1%<br>0.0%<br>-1.4%<br>3.4%<br>-2.4%<br>1.8%   | 0.5% -0.5% -15.9% -14.9% -6.5% -12.8% -4.3% -0.9% -17.9% -0.9% -17.9% -0.9% -12.7%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 66.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 16.1 197.6  | na 22.0 26.8 12.6 na 2.8 na 18.1 na na 64.8 35.0 25.8 11.6 8.0 8.5 6.6   | na 13.2 14.0 12.5 na 1.8 na 15.8 na 12 21.1 20.6 11.3 6.8 7.7 6.1   | na 8.2 8.2 7.9 na 3.0 na 9.5 na na 15.8 15.3 6.8 5.0 5.3  | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.9 3.0   | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  3.7%  3.1%   | na 0.4% 0.6% 0.6% 5.6% 0.0% 0.1% 0.0% 1.9% 0.0% 1.43% 4.3% 6.0% 6.0%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLITREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD PEKABEX   | HOLD HOLD BUY             | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20   | -13%<br>58%<br>33%<br>51%<br>-4%<br>48%<br>82%<br>19%<br>-22%<br>-19%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>54.60<br>194.20<br>69.00<br>137.00<br>88.60  | 3.5%  1.2% 0.0% -3.19 3.8% 0.4% 1.4% -1.19 3.4% -2.4% 1.8%   | -0.5%<br>-0.5%<br>15.9%<br>-14.9%<br>6.5%<br>-12.8%<br>-4.3%<br>10.4%<br>-5.0%<br>17.9%<br>63.0%<br>12.7%  | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 66.7 926.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 16.1 197.6 130.2   | na  22.0  26.8  12.6  na  2.8  na  18.1  na  64.8  35.0  25.8  11.6  8.0  8.5  6.6   | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 1.2 21.1 20.6 7.7 6.1 6.8  | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  15.3  5.0  5.3  3.6  | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.5 4.9 3.0 4.6   | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  3.1%  5.6%  3.1%   | na  0.4% 0.6% 0.6% 5.6% 0.0% 0.1% 0.0% 0.0% 1.9% 0.0% 4.3% 6.0% 9.5% 6.0% 6.0%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD  | HOLD HOLD BUY             | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20   | -13%<br>58%<br>33%<br>51%<br>-4%<br>48%<br>82%<br>19%<br>-22%<br>-19%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>55.00<br>54.60<br>194.20<br>69.00<br>137.00<br>88.60<br>7,399.00<br>9.24<br>22.50  | 3.5%<br>1.2%<br>0.0%<br>-3.1%<br>3.8%<br>0.4%<br>1.4%<br>-1.1%<br>0.0%<br>-1.4%<br>3.4%<br>-2.4%<br>1.8%   | 0.5% -0.5% -15.9% -14.9% -6.5% -12.8% -4.3% -0.9% -17.9% -0.9% -17.9% -0.9% -12.7%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 66.7 926.8 59.8 301.7 123.4 295.2 277.3 216.9  MEDIAN 16.1 197.6 130.2  MEDIAN  | na 22.0 26.8 12.6 na 2.8 na 18.1 na na 64.8 35.0 25.8 11.6 8.0 8.5 6.6   | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 1.2 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7  | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  5.0  6.9   | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.9 3.0 4.6 5.9   | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  0.0%  3.1%  3.1%  5.6%  3.1%  5.6%  1.9%   | na 0.496 0.696 0.096 0.096 0.196 0.096  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNLEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY  | HOLD HOLD BUY             | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20   | -13%<br>58%<br>33%<br>51%<br>-4%<br>48%<br>82%<br>19%<br>-22%<br>-19%   | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>55.00<br>54.60<br>194.20<br>69.00<br>137.00<br>88.60   | 3.5%  1.2% 0.0% -3.1% 3.8% 0.4% -1.19 0.0% -1.49 3.4% -2.49 1.8%  0.0% -12.0% 1.4%   | 0.5%<br>-0.5%<br>15.9%<br>-14.9%<br>6.5%<br>-12.8%<br>-4.3%<br>10.4%<br>-5.0%<br>17.9%<br>63.0%<br>12.7%<br>5.5%<br>12.8%<br>3.2%  | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 66.7 926.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 16.1 197.6 130.2   | na  22.0  26.8  12.6  na  2.8  na  18.1  na  na  64.8  35.0  25.8  11.6  8.0  8.5  6.6  8.0  | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 1.2 21.1 20.6 7.7 6.1 6.8  | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  15.3  5.0  5.3  3.6  | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.5 4.9 3.0 4.6   | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  3.1%  5.6%  3.1%   | na  0.4% 0.6% 0.6% 5.6% 0.0% 0.1% 0.0% 0.0% 1.9% 0.0% 4.3% 6.0% 9.5% 6.0% 6.0%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LPP   | HOLD BUY                  | 111.00<br>41.20<br>5,64<br>25,60<br>849.00<br>81.40<br>99.30<br>70.00<br>106.60<br>72.20<br>6.430.00<br>10.00  | -13%<br>55%<br>33%<br>51%<br>-4%<br>45%<br>62%<br>19%<br>-12%<br>-13%<br>89%  | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>55.00<br>54.60<br>194.20<br>69.00<br>137.00<br>88.60<br>7,399.00<br>9.24<br>22.50<br>2,920.00<br>73.10<br>15,200.00  | 3.5% 1.2% 0.0% -3.1% 3.8% 0.4% 1.4% -1.19% -2.4% 1.8% 0.0% -1.4% 1.4% 1.8%   | 0.5%<br>15.9%<br>14.9%<br>6-14.9%<br>6-12.8%<br>-4.3%<br>10.4%<br>6-5.0%<br>-0.9%<br>12.7%<br>12.8%<br>3.2%<br>49.7%<br>19.5%<br>6-6.1%  | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 666.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9 MEDIAN 16.1 197.6 130.2 MEDIAN 2,038.8 1,173.2 6,571.8   | na  22.0  26.8  12.6  na  2.8  na  18.1  na  na  64.8  35.0  25.8  11.6  8.0  8.5  6.6  8.0  15.5  19.9  80.4  14.1  | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 1.2 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7  | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  15.3  6.8  5.0  5.0  6.9  10.5  7.5  | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.6 4.9 3.0 4.6 5.9 8.9 6.4 6.3   | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  0.0%  3.7%  3.1%  2.6%  3.7%  0.0%  0.0%  4.0%   | na  0.4% 0.6% 5.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 6.0% 2.6% 4.3% 4.2% 0.0% 6.0% 6.0% 6.0% 6.0% 6.0% 6.0% 6.0   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTYO SEVOJNO MIRBUID PEKABEX CONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LPP MIRACULUM  | HOLD BUY                  | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20<br>6,430.00<br>10.00  | -13%<br>55%<br>53%<br>51%<br>-4%<br>82%<br>19%<br>-22%<br>-19%<br>-13%<br>8%  | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>54.60<br>194.20<br>69.00<br>137.00<br>88.60<br>7,399.00<br>9.24<br>22.50<br>2,920.00<br>73.10<br>15,200.00<br>11.30                                    | 3.5%  1.2% 0.0% -3.1% 3.8% 1.4% 1.4% -1.1% -2.4% 1.8%  0.0% -12.0% 1.4% 1.9% 1.9% 4.4%   | 0.5%<br>15.9%<br>15.9%<br>1-14.9%<br>6.5%<br>1-2.8%<br>10.4%<br>10.4%<br>17.9%<br>63.0%<br>12.7%<br>12.7%<br>12.8%<br>3.2%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 66.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 16.1 197.6 130.2  MEDIAN 2,038.8 1,173.2 6,571.8  | na  22.0  26.8  12.6  na  2.8  na  18.1  na  na  64.8  35.0  25.8  11.6  8.0  15.5  19.9  80.4  14.1  67.0   | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 1.2 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9  | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  15.3  6.8  5.0  6.9  10.5  7.8  7.5  24.2  | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.6 4.9 3.0 4.6 5.9 8.9 6.4 6.3 14.6  | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  0.0%  3.7%  5.6%  3.1%  2.6%  1.9%  3.7%  0.0%   | na  0.4% 0.6% 0.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SVNEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY BENERIT SYSTEMS CCC LPP MIRACULUM PEPCO GROUP   | HOLD BUY                  | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>70.00<br>106.60<br>72.20<br>6,430.00<br>10.00<br>2,390.00<br>57.10<br>15,800.00<br>1.35<br>25.00                                     | -13%<br>55%<br>33%<br>51%<br>48%<br>48%<br>82%<br>19%<br>-22%<br>48%<br>38%   | 9.20  15.38 127.50 26.00 4.24 17.00 885.00 55.00 54.60 194.20 69.00 137.00 88.60  7,399.00 9.24 22.50 2,920.00 73.10 15,200.00 1.30   | 3.5%  1.2% 0.0% -3.1% 3.8% 0.4% 1.4% -1.1% -2.4% 1.8% -2.4% 1.8% -1.2.0% -1.4% 1.4% 1.5% 4.4% 0.7%   | 0.5%<br>15.9%<br>14.9%<br>6.5%<br>10.4%<br>5.0%<br>10.4%<br>55.0%<br>12.7%<br>12.8%<br>3.2%<br>63.0%<br>63.0%<br>63.0%<br>63.0%<br>63.0%<br>63.0%<br>12.7%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 666.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 197.6 130.2  MEDIAN 2,038.8 1,173.2 6,571.8 14.2 2,391.3   | na  22.0  26.8  12.6  na  2.8  na  18.1  na  64.8  35.0  25.8  11.6  8.0  15.5  19.9  80.4  14.1  67.0  16.9   | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 1.2 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9  | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  5.0  6.9  10.5  7.8  7.5  24.2  5.1  | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.9 3.0 4.6 5.9 8.9 6.4 6.3 14.6 4.4  | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  0.0%  0.0%  0.0%  0.0%  3.7%  3.1%  5.6%  3.1%  2.6%  1.9%  0.0%   | na  0.4% 0.6% 5.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 6.0% 4.3% 6.0% 4.2% 6.0% 5.0% 0.0% 0.0% 0.0% 0.0% 0.0%   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYWL THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTYO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LIPP MIRACULUM PEPCO GROUP PURCARI WINERIES   | HOLD BUY                  | 111.00<br>41.20<br>5,64<br>25.60<br>849.00<br>81.40<br>99.30<br>106.60<br>72.20<br>6.430.00<br>10.00<br>57.10<br>15,800.00<br>1.35<br>25.00  | -13% 55% 53% 55% 55% 55% 55% 55% 55% 55% 5  | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>55.00<br>54.60<br>194.20<br>69.00<br>137.00<br>88.60<br>7,399.00<br>9.24<br>22.50<br>2,920.00<br>73.10<br>15,200.00<br>1,30<br>17.85<br>17.85<br>15.40 | 3.5% 1.2% 0.0% -3.1% 3.8% 0.4% 1.4% -1.1% 0.0% -2.4% 1.4% 1.2% 1.4% 1.9% 1.4% 1.9% 1.4% 0.0% 0.0%  | 0.5% 15.9% 15.9% 14.9% 6.5% 10.4% -5.0% 10.4% 5.5% 12.8% 3.2% 49.7% 19.5% 6.1% 1.2% 7.4%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 666.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9 MEDIAN 16.1 197.6 130.2 MEDIAN 2,038.8 1,173.2 6,571.8 14.2 2,391.3 124.3  | na  22.0  26.8  12.6  na  2.8  na  18.1  na  na  64.8  35.0  25.8  11.6  8.0  15.5  19.9  80.4  14.1  67.0  16.9  10.4   | na 13.2 14.0 12.5 na 1.8 na 15.8 na 12 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9 13.4 12.0  | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  5.0  5.3  3.6  5.0  10.5  7.8  7.5  24.2  5.1  6.4   | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.6 4.9 3.0 4.6 5.9 8.9 6.4 4.4 5.6   | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  1.3%  3.1%  5.6%  3.1%  2.6%  1.9%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%   | na  0.4% 0.6% 0.6% 0.0% 0.0% 0.0% 0.0% 1.9% 0.0% 0.0% 2.1% 0.0% 2.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLITREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LPP MIRACULUM PEPCO GROUP PURCARI WINERIES VRG   | HOLD BUY                  | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20<br>6,430.00<br>10.00<br>57.10<br>15,800.00<br>1.35<br>25.00<br>15.60                              | -13% 55% 53% 53% 53% 65% 51% 45% 64% 64% 64% 64% 64% 64% 64% 64% 64% 64   | 9.20  15.38 127.50 26.00 4.24 17.00 885.00 55.00 54.60 194.20 69.00 137.00 88.60  7,399.00 9.24 22.50 2,920.00 1.30 17.85 15.40 3.15  | 3.5%  1.2% 0.0% -3.1% 3.1% 0.4% 1.4% 0.0% -1.1% -1.1% -1.1% -1.4% 1.8% -1.2.0% 1.4% 1.9% 1.5% 4.4% 0.7% 0.0%   | 0.5% 10.5% 15.9% 14.9% 6.5% 10.4% 6.50% 10.4% 5.00% 12.7% 12.8% 3.2% 49.7% 49.7% 49.7% 49.7% -6.1% 1.5% -7.4%  | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 666.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 105.1 197.6 130.2  MEDIAN 2,038.8 1,173.2 6,571.8 14.2 2,391.3 124.3 172.1   | na  22.0  26.8  12.6  na  2.8  na  18.1  na  64.8  35.0  25.8  11.6  8.0  15.5  19.9  80.4  14.1  67.0  16.9  10.4  8.3  | na 13.2 14.0 12.5 na 1.8 na 15.8 na 1.2 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9 13.4 12.0 7.9   | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  15.3  6.8  5.0  6.9  10.5  7.8  7.5  24.2  5.1  6.4  3.8   | na  8.2  6.3  8.1  126.0  2.2  na  8.4  na  na  11.8  12.3  6.6  4.9  3.0  4.6  5.9  8.9  6.4  6.3  14.6  4.4  5.6  3.5                                | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  0.0%  3.7%  3.1%  5.6%  3.1%  5.6%  3.7%  0.0%   | na  0.4% 0.6% 5.6% 0.0% 0.0% 0.0% 0.0% 0.0% 1.9% 0.0% 1.9% 6.0% 2.1% 6.0% 6.0% 6.0% 6.0% 6.0% 6.0% 6.0% 6.0   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLITREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LIP MIRACULUM PEPCO GROUP PURCARI WINERIES VRG WITTCHEN  | HOLD BUY                  | 111.00<br>41.20<br>5,64<br>25.60<br>849.00<br>81.40<br>99.30<br>106.60<br>72.20<br>6.430.00<br>10.00<br>57.10<br>15,800.00<br>1.35<br>25.00  | -13% 55% 53% 55% 55% 55% 55% 55% 55% 55% 5  | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>55.00<br>54.60<br>194.20<br>69.00<br>137.00<br>88.60<br>7,399.00<br>9.24<br>22.50<br>2,920.00<br>73.10<br>15,200.00<br>1,30<br>17.85<br>17.85<br>15.40 | 3.5% 1.2% 0.0% -3.1% 3.8% 0.4% 1.4% -1.1% 0.0% -2.4% 1.4% 1.2% 1.4% 1.9% 1.4% 1.9% 1.4% 0.0% 0.0%  | 0.5% 15.9% 15.9% 14.9% 6.5% 10.4% -5.0% 10.4% 5.5% 12.8% 3.2% 49.7% 19.5% 6.1% 1.2% 7.4%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 666.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9 MEDIAN 197.6 197.6 197.6 2,038.8 1,173.2 6,571.8 14.2 2,391.3 124.3 172.1 119.8  | na  22.0  26.8  12.6  na  18.1  na  na  64.8  35.0  25.8  11.6  8.0  15.5  19.9  80.4  14.1  67.0  16.9  10.4  8.3  7.9  | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 1.2 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9 13.4 12.0 7.9 7.2                                    | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  15.3  6.8  5.0  5.3  3.6  5.9  10.5  7.8  7.5  24.2  5.1  6.4  3.8  5.1                                | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.5 4.9 3.0 4.6 5.9 8.9 6.4 6.3 14.6 4.4 5.6 3.5 4.6  | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  0.0%  0.0%  0.0%  0.0%  3.7%  3.1%  2.6%  3.7%  0.0%  0.0%  0.0%  5.5%  3.7%  0.0%  0.0%  0.0%  5.5%  3.7%  0.0%  0.0%  0.0%  0.0%  5.5%  3.7%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%   | na  0.4% 0.6% 5.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 1.9% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LIP MIRACULUM PEPCO GROUP PURCARI WINERIES VRG WITTCHEN CONSUMER STAPLES  | HOLD BUY                  | 111.00<br>41.20<br>5,64<br>25,60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20<br>6,430.00<br>10.00<br>57.10<br>15,800.00<br>1.35<br>25.00<br>3.93<br>38.20                      | -13% 55% 53% 55% 55% 55% 55% 55% 55% 55% 5  | 9.20<br>15.38<br>127.50<br>26.00<br>4.24<br>17.00<br>885.00<br>54.60<br>194.20<br>69.00<br>137.00<br>88.60<br>7,399.00<br>9,24<br>22.50<br>2,920.00<br>73.10<br>15,200.00<br>130.17,85<br>15,40<br>3,15<br>28.00      | 3.5%  1.2% 0.0% -3.18% 3.8% 0.4% 1.4% 0.0% -1.19% -2.4% 1.8% -1.20% 1.4% 1.9% 1.5% -2.4% 1.5% -2.4% 1.5% -2.4% 1.5% -2.4% 1.5% -2.4% | 0.5% 15.9% 15.9% 1-14.9% 6.5% 10.4% -5.09% 12.7% 63.0% 12.7% 13.5% 1.2% 49.7% 19.5% 6.19% 7.4% 7.4% 7.4%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 66.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 16.1 197.6 130.2  MEDIAN 2,038.8 1,173.2 6,571.8 14.2 2,391.3 124.3 172.1 119.8  MEDIAN                                       | na  22.0  26.8  12.6  na  2.8  na  18.1  na  na  64.8  35.0  25.8  11.6  8.0  15.5  19.9  80.4  14.1  67.0  16.9  10.4  8.3  7.9  12.7                               | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 12.2 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9 13.4 12.0 7.9 7.9 12.1                              | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  15.3  6.8  5.0  5.0  6.9  10.5  7.8  7.5  24.2  5.1  6.4  3.8  | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.6 4.9 3.0 4.6 5.9 8.9 6.4 4.4 5.6 3.5 4.6 5.6 5.6   | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  1.3%  3.1%  5.6%  3.1%  2.6%  3.7%  0.0%  0.0%  0.0%  0.0%  2.6%  2.6%  2.6%  2.0%   | na  0.4% 0.6% 0.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLITREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LPP MIRACULUM PEPCO GROUP PURCARI WINERIES VRG WITTCHEN CONSUMER STAPLES AMREST  | HOLD BUY                  | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20<br>6,430.00<br>10.00<br>2,390.00<br>57.10<br>15,800.00<br>1.35<br>25.00<br>15.60<br>3.93<br>38.20 | -13% 55% 53% 53% 53% 53% 53% 53% 53% 53% 5  | 9,20<br>15,38<br>127,50<br>26,00<br>4,24<br>17,00<br>55,00<br>54,60<br>194,20<br>69,00<br>37,00<br>88,60<br>7,399,00<br>9,24<br>22,50<br>2,920,00<br>1,30<br>17,85<br>15,40<br>3,15<br>28,00                          | 3.5%  1.2% 0.0% -3.1% 0.4% 1.4% -1.19 0.0% -1.4% 3.4% -2.4% -1.2.0% 1.8%  1.5% 4.4% 0.7% 0.0% -1.5% 4.4% 1.5% 4.4% 1.5% 4.4% 1.5% 4.4% 1.5% 4.4% 1.5% 4.4% 1.5% 4.4% 1.5% 4.4% 1.5% 4.4% 1.5% 1.5% 4.4% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5   | 0.5% 15.9% 14.9% 6.5% 11.28% 1-4.3% 10.4% 10.4% 10.9% 11.27% 12.8% 12.7% 12.8% 12.7% 12.8% 12.7% 12.8% 12.7%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 666.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9 MEDIAN 2,038.8 1,173.2 6,571.8 14.2 2,391.3 124.3 172.1 119.8  MEDIAN 1,238.3  | na  22.0  26.8  12.6  na  2.8  na  18.1  na  64.8  35.0  25.8  11.6  8.0  15.5  19.9  80.4  14.1  67.0  16.9  10.4  8.3  7.9  12.7                                   | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 1.2 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9 13.4 12.0 7.9 7.2 11.1                               | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  5.0  6.9  10.5  7.8  7.5  24.2  5.1  6.4  3.8  5.1  6.4  | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.9 3.0 4.6 5.9 8.9 6.4 6.3 14.6 4.4 5.6 3.5 4.6 5.6 4.9  | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  3.7%  3.1%  5.6%  3.1%  5.6%  3.1%  0.0%  0.0%  0.0%  0.0%  2.6%  1.9%  2.6%  2.6%  2.6%  3.7%  3. | na  0.4% 0.6% 5.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LIP MIRACULUM PEPCO GROUP PURCARI WINERIES VRG WITTCHEN CONSUMER STAPLES  | HOLD BUY                  | 111.00<br>41.20<br>5,64<br>25,60<br>849.00<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20<br>6,430.00<br>10.00<br>57.10<br>15,800.00<br>1.35<br>25.00<br>3.93<br>38.20                      | -13%<br>55%<br>33%<br>51%<br>44%<br>45%<br>82%<br>11%<br>-22%<br>-19%<br>85%<br>44%<br>40%<br>40%<br>40%<br>55%<br>36%<br>66%                     | 9.20  15.38 127.50 26.00 4.24 17.00 885.00 55.00 54.60 194.20 69.00 137.00 88.60  7,399.00 9.24 22.50  2,920.00 73.10 15,200.00 1.30 17.85 15.40 3.15 28.00 24.20 56.50   | 3.5% 1.2% 0.0% -3.1% 3.8% 0.4% 1.4% -1.1% 0.0% -1.4% 1.4% 1.2.4% 1.8% 1.4% 1.9% 1.4% 1.6% -0.0% -1.6%  | 0.5% 15.9% 15.9% 1-14.9% 6.5% 10.4% -5.09% 12.7% 63.0% 12.7% 13.5% 1.2% 49.7% 19.5% 6.19% 7.4% 7.4% 7.4%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 66.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 16.1 197.6 130.2  MEDIAN 2,038.8 1,173.2 6,571.8 14.2 2,391.3 124.3 172.1 119.8  MEDIAN                                       | na  22.0  26.8  12.6  na  2.8  na  18.1  na  na  64.8  35.0  25.8  11.6  8.0  15.5  19.9  80.4  14.1  67.0  16.9  10.4  8.3  7.9  12.7                               | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 12.2 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9 13.4 12.0 7.9 7.9 12.1                              | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  15.3  6.8  5.0  5.0  6.9  10.5  7.8  7.5  24.2  5.1  6.4  3.8  | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.6 4.9 3.0 4.6 5.9 8.9 6.4 4.4 5.6 3.5 4.6 5.6 5.6   | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  1.3%  3.1%  5.6%  3.1%  2.6%  3.7%  0.0%  0.0%  0.0%  0.0%  2.6%  2.6%  2.6%  2.0%   | na  0.4% 0.6% 0.6% 0.0% 0.0% 0.0% 0.0% 1.9% 0.0% 0.0% 2.6% 9.5% 6.0% 2.6% 4.2% 0.0% 0.0% 6.1% 6.0% 6.1% 6.4%  |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTYO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LIPP MIRACULUM PEPCO GROUP PURCARI WINERIES VRG WITTCHEN CONSUMER STAPLES AMREST ATLANTIC GRUPA DINO POLSKA                           | HOLD BUY                  | 111.00<br>41.20<br>5.64<br>25.60<br>81.40<br>99.30<br>230.20<br>70.00<br>106.60<br>72.20<br>6,430.00<br>10.00<br>57.10<br>15,800.00<br>15.60<br>3.93<br>38.20  | -13% 55% 53% 53% 53% 53% 53% 53% 53% 53% 5  | 9,20  15,38 127,50 26,00 4,24 17,00 58,500 54,60 194,20 69,00 137,00 88,60  7,399,00 9,24 22,50  2,920,00 73,10 15,200,00 17,85 15,40 3,15 28,00  | 3.5% 1.2% 0.0% -3.1% 3.8% 0.4% -1.1% 0.0% -1.4% 3.4% -2.4% -1.2.0% 1.8% 1.9% 1.5% 4.4% 0.7% 0.0% -1.6% -1.6% -1.6% -1.6% -1.6% -1.3% -1.3%   | 0.5% 10.5% 15.9% 14.9% 6.5% 14.9% 6.5% 10.4% 5.0% 17.9% 12.7% 12.8% 3.15% 49.7% 19.5% -6.19% -7.4% -7.0%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 66.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 130.2  MEDIAN 2,038.8 1,173.2 6,571.8 14.2 2,391.3 124.3 172.1 119.8  MEDIAN 1,238.3 748.4 8,579.6                            | na  22.0  26.8  12.6  na  2.8  na  18.1  na  64.8  35.0  25.8  11.6  8.0  15.5  19.9  80.4  14.1  67.0  16.9  10.4  8.3  7.9  11.1  14.7  19.6                       | na 13.2 14.0 12.5 na 1.8 na 15.8 na 1.2 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9 13.4 12.0 7.9 7.2 11.1 9.1 11.9 15.5                    | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  5.0  5.3  3.6  5.0  6.9  10.5  7.8  7.5  24.2  5.1  6.4  3.8  5.1  6.4  6.9  13.0                      | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.9 3.0 4.6 5.9 8.9 6.4 6.3 14.6 4.4 5.6 5.5 4.9 5.9 5.9 10.3                                     | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  0.0%  3.7%  3.1%  5.6%  3.1%  5.6%  3.7%  0.0%  4.0%  0.0%  4.0%  0.0%  4.0%  0.0%  5.9%  5.9%  5.9%  0.0%   | na  0.4% 0.6% 5.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLITREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTYO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LPP MIRACULUM PEPCO GROUP PURCARI WINERIES VRG WITTCHEN CONSUMER STAPLES AMREST ATLANTIC GRUPA                                       | HOLD BUY                  | 111.00<br>41.20<br>5,64<br>25.60<br>849.00<br>81.40<br>99.30<br>106.60<br>72.20<br>6.430.00<br>10.00<br>57.10<br>15,800.00<br>1.35<br>25.00<br>3.39<br>38.20   | -13% 55% 53% 55% 55% 65% 65% 65% 55% 65% 55% 65% 65   | 9.20  15.38 127.50 26.00 4.24 17.00 885.00 55.00 54.60 194.20 69.00 137.00 88.60  7,399.00 9.24 22.50  2,920.00 73.10 15,200.00 1.30 17.85 15.40 3.15 28.00 24.20 56.50   | 3.5% 1.2% 0.0% -3.1% 3.8% 0.4% 1.4% -1.1% 0.0% -1.4% 1.4% 1.2.4% 1.8% 1.4% 1.9% 1.4% 1.6% -0.0% -1.6%  | 0.5% -0.5% 15.9% -14.9% 6.5% -12.8% 4.3% 10.4% -5.0% 12.7% 12.7% 12.8% 3.2% -6.1% 1.2% -31.5% -7.4% -7.4% -7.0% -9.0%  | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 666.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9 MEDIAN 16.1 197.6 130.2 MEDIAN 2,038.8 1,173.2 6,571.8 14.2 2,391.3 124.3 172.1 119.8 MEDIAN 1,238.3 748.4                           | na  22.0  26.8  12.6  na  2.8  na  18.1  na  na  64.8  35.0  25.8  11.6  8.0  8.5  6.6  8.0  15.5  19.9  80.4  14.1  67.0  16.9  10.4  8.3  7.9  12.7                | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 12.2 11.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9 13.4 12.0 7.9 7.2 11.1 9.1 11.9                     | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  15.3  6.8  5.0  5.0  10.5  7.8  7.5  24.2  5.1  6.4  3.8  5.1  6.4  5.4  6.9                           | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.6 4.6 4.9 3.0 4.6 5.9 8.9 6.4 6.3 14.6 4.4 5.6 3.5 4.6 4.9 5.9 5.9                              | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  0.0%  0.0%  1.3%  3.1%  5.6%  3.1%  2.6%  0.0%  0.0%  0.0%  5.9%  0.0%  0.0%  0.0%  3.7%  3.1%   | na  0.4% 0.6% 5.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLITREG RYVU THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTVO SEVOJNO MIRBUD PEKABEX COCONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LIP MIRACULUM PEPECO GROUP PURCARI WINERIES VAG WITTCHEN CONSUMER STAPLES AMMEST ALLANTIC GRUPA DINO POLSKA EUINOCASH              | HOLD BUY                  | 111.00<br>41.20<br>5.64<br>25.60<br>849.00<br>81.40<br>99.30<br>106.60<br>72.20<br>6.430.00<br>10.00<br>2,390.00<br>1,35<br>25.00<br>15.60<br>3.93<br>38.20  | -13% 55% 53% 53% 53% 53% 53% 54% 54% 54% 54% 54% 54% 54% 54% 54% 54   | 9.20  15.38 127.50 26.00 4.24 17.00 885.00 55.00 54.60 194.20 69.00 137.00 88.60  7.399.00 9.24 22.50 2,920.00 1.30 1.30 17.85 15.40 3.15 28.00 24.20 56.50 375.50 375.50   | 3.5% 1.2% 0.0% -3.1% 3.8% 0.4% 1.4% -1.196 3.4% -2.4% 1.8% -12.0% 1.4% 1.5% 4.4% 0.0% -1.5% -3.4% 1.5% -3.4% 0.0% -1.3% -3.4% 0.0% -0.03   | 0.5%  15.9% 14.9% 6.5% 10.4% -5.0% 112.8% 12.7% 12.8% 3.2% 49.7% 19.5% 6.11% -7.4% -7.4% -7.4% -7.0% -9.0% 0.0% -18.5%   | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 66.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 2,038.8 1,173.2 6,571.8 14.2 2,391.3 124.3 172.1 119.8  MEDIAN 1,283.3 748.4 8,579.6 453.1                                    | na  22.0  26.8  12.6  na  18.1  na  na  64.8  35.0  25.8  11.6  8.0  15.5  19.9  8.0  14.1  67.0  10.4  8.3  7.9  12.7  11.1  14.7  19.6  10.1                       | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 1.2 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9 13.4 12.0 7.9 7.2 11.1 9.1 11.9 15.5 7.0             | na  8.2  8.2  7.9  na 3.0  na 9.5  na 15.8  5.0  6.9  10.5  7.8  7.5  24.2  5.1  6.4  3.8  5.1  6.4  6.9  13.0  3.9                                   | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na na 11.8 12.3 6.6 4.6 4.6 5.9 8.9 6.4 6.3 14.6 4.4 5.6 3.5 4.6 5.6 5.6 4.9 3.0 3.5 3.5 3.5 3.5                   | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  0.0%  0.0%  0.0%  0.0%  1.3%  3.1%  2.6%  3.1%  2.6%  0.0%  0.0%  0.0%  3.1%  2.6%  3.7%  0.0%   | na  0.496 0.696 0.696 0.096   |
| BIOTECH & HEALTHCARE CELON PHARMA KRKA MEDICALGORITHMICS MEDLIFE MOLECURE NEUCA POLTREG RYWL THERAPEUTICS SCOPE FLUIDICS SELVITA SYNEKTIK VOXEL CONSTRUCTION JEDINSTYO SEVOJNO MIRBUD PEKABEX CONSUMER DISCRETIONARY BENEFIT SYSTEMS CCC LIPP MIRACULUM PEPCO GROUP PURCARI WINERIES VRG WITTCHEN CONSUMER STAPLES AMREST ATLANTIC GRUPA DINO POLSKA EUROCASH JERONIMO MARTINS | HOLD BUY                  | 111.00<br>41.20<br>5,64<br>25,60<br>849.00<br>81.40<br>99.30<br>106.60<br>72.20<br>6,430.00<br>10.00<br>57.10<br>15,800.00<br>1.35<br>25.00<br>3.39<br>38.20   | -13%<br>55%<br>33%<br>51%<br>44%<br>82%<br>11%<br>-22%<br>-19%<br>-13%<br>8%<br>8%<br>40%<br>40%<br>40%<br>25%<br>36%<br>66%<br>68%<br>88%<br>88% | 9.20  15.38 127.50 26.00 4.24 17.00 885.00 55.00 54.60 194.20 69.00 137.00 88.60  7,399.00 9.24 22.50  2,920.00 73.10 15,200.00 1.30 17.85 28.00 24.20 56.50 375.50 13.97 18.24                                       | 3.5%  1.2% 0.0% -3.1% 0.0% -3.18% 0.4% 1.4% -1.19 0.0% -1.4% 1.4% 1.9% 1.4% 1.9% 1.6% -0.03 1.3% 0.0% -1.6% -1.4%  | 0.5%  15.9% 15.9% 14.3% 6.5% 10.4% -5.0% 10.4% 17.9% 63.0% 12.7% 12.8% 3.2%  49.7% 19.5% 1.2% -6.1% 1.2% -7.4% | 643.3  MEDIAN 184.4 4,182.0 60.3 113.4 666.7 926.8 59.8 301.7 123.4 295.2 272.3 216.9  MEDIAN 16.1 197.6 130.2  MEDIAN 2,038.8 1,173.2 6,571.8 14.2 2,391.3 124.3 172.1 119.8  MEDIAN 1,238.3 748.4 8,579.6 453.1 11,478.3 | na  22.0  26.8  12.6  na  18.1  na  na  64.8  35.0  25.8  11.6  8.0  8.5  6.6  8.0  15.5  19.9  80.4  14.1  67.0  16.9  10.4  8.3  7.9  12.7  11.1  19.6  10.1  13.0 | na 13.2 14.0 12.5 na 1.8 na 15.8 na na 15.8 na 12 21.1 20.6 11.3 6.8 7.7 6.1 6.8 12.7 17.2 25.9 12.0 24.9 13.4 12.0 7.9 7.2 11.1 9.1 11.9 15.5 7.0 11.5 | na  8.2  8.2  7.9  na 3.0  na 9.5  na na 15.8  15.3  6.8  5.0  5.3  3.6  5.0  10.5  7.8  7.5  24.2  5.1  6.4  3.8  5.1  6.4  5.4  6.9  13.0  3.9  5.7 | na  8.2 6.3 8.1 126.0 2.2 na 8.4 na na 11.8 12.3 6.6 4.6 4.5 4.9 3.0 4.6 5.9 8.9 6.4 4.4 5.6 6.3 14.6 4.4 5.6 3.5 4.6 5.6 3.5 5.6 4.9 5.9 10.3 3.5 5.9 | na  0.0%  0.6%  5.2%  0.0%  0.1%  0.0%  1.6%  0.0%  1.6%  5.2%  0.0%  0.0%  1.3%  3.1%  5.6%  3.1%  2.6%  1.9%  2.6%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  0.0%  1.3%  3.1%  2.6%  0.0%   | na  0.496 0.698 5.69% 0.096 0.096 0.096 1.996 0.096 1.996 0.096 1.996 0.096 1.996 0.096 1.996 0.096 1.996 0.096 1.996 0.096 1.996 0.096 1.996 0.096 1.996 0.096 |

|                                    | Recomm-     | Fair Value        | Upside /    | Current           | Perforn       | nance           | Market Cap          | P/E                |                    | EV/EBITDA         |                   | DY            |               |
|------------------------------------|-------------|-------------------|-------------|-------------------|---------------|-----------------|---------------------|--------------------|--------------------|-------------------|-------------------|---------------|---------------|
| Company                            | endation    | (Local)           | downside    | Price (Local)     | 1D            | YTD             | in EUR m            | 2024E              | 2025E              | 2024E             | 2025E             | 2024E         | 2025E         |
| E-COMMERCE                         |             |                   |             |                   |               |                 | MEDIAN              | 23.7               | 18.2               | 11.6              | 9.2               | 0.0%          | 0.0%          |
| ALLEGRO                            | BUY         | 36.90             | 17%         | 31.66             | -1.4%         | -5.0%           | 7,797.0             | 24.4               | 17.2               | 12.1              | 9.3               | 0.0%          | 0.0%          |
| INPOST                             | BUY         | 12.30             | -14%        | 14.25             | -1.7%         | 13.9%           | 7,125.0             | 23.0               | 19.2               | 11.1              | 9.2               | 0.0%          | 0.0%          |
| ELECTRIC UTILITIES                 |             |                   |             |                   |               |                 | MEDIAN              | 6.1                | 9.0                | 4.5               | 4.4               | 7.7%          | 7.9%          |
| CEZ                                | BUY         | 1,025.91          | 23%         | 835.50            | 1.2%          | -12.8%          | 17,706.7            | 10.5               | 8.9                | 4.4               | 3.8               | 8.4%          | 9.6%          |
| ELECTRICA                          | U/R         |                   |             | 13.38             | -0.6%         | 16.6%           | 914.4               | 9.1                | 9.0                | 4.6               | 3.8               | 7.7%          | 7.9%          |
| ENEA                               | SELL        | 5.78              | -42%        | 9.95              | 2.7%          | 8.5%            | 1,228.4             | 4.5                | 4.4                | 3.7               | 3.7               | 2.0%          | 6.6%          |
| HIDROELECTRICA<br>NUCLEARELECTRICA | HOLD<br>BUY | 125.50            | -5%<br>8%   | 132.00<br>48.25   | 0.0%<br>-0.5% | 3.1%<br>-1.7%   | 11,949.8<br>2,929.2 | 11.3               | 10.1<br>6.3        | 8.2<br>3.3        | 7.4<br>5.0        | 8.0%<br>11.3% | 8.9%<br>11.5% |
| PGE PGE                            | SELL        | 52.00<br>6.15     | -16%        | 48.25<br>7.33     | 0.5%          | -1.7%<br>-15.5% | 2,929.2<br>3,832.9  | 6.1<br>4.0         | 5.2                | 3.3               | 3.4               | 2.5%          | 7.5%          |
| PHOTON ENERGY                      | U/R         | 0.15              | -1090       | 7.52              | -0.3%         | -7.4%           | 107.3               | na                 | 35.1               | 19.6              | 14.9              | na            | na            |
| POLENERGIA                         | U/R         |                   |             | 68.20             | 0.3%          | -11.2%          | 974.5               | 12.3               | 13.4               | 8.6               | 9.3               | na            | na            |
| TAURON                             | SELL        | 3.14              | 0%          | 3.13              | 0.7%          | -16.2%          | 1,278.4             | 2.5                | 3.1                | 3.0               | 3.1               | 6.9%          | 4.0%          |
| TRANSELECTRICA                     | U/R         |                   |             | 29.50             | -0.7%         | -2.0%           | 435.2               | na                 | na                 | na                | na                | na            | na            |
| ZE PAK                             | U/R         |                   |             | 19.54             | -0.2%         | -9.5%           | 231.4               | 4.6                | 9.3                | 5.4               | 14.6              | na            | na            |
| INDUSTRIALS                        |             |                   |             |                   |               |                 | MEDIAN              | 10.7               | 9.1                | 6.8               | 6.5               | 4.9%          | 5.0%          |
| AC                                 | U/R         |                   |             | 29.90             | -0.3%         | 15.0%           | 70.2                | 10.7               | 10.5               | 6.8               | 6.7               | 8.4%          | 11.7%         |
| AMICA                              | U/R         |                   |             | 71.10             | -1.3%         | -14.3%          | 128.8               | 12.2               | 7.6                | 4.2               | 3.5               | 1.6%          | 3.6%          |
| CINKARNA CELJE                     | SELL        | 20.00             | -7%         | 21.60             | 0.9%          | 21.5%           | 174.5               | 20.9               | 32.0               | 7.8               | 8.5               | 0.0%          | 14.8%         |
| GRUPA KETY                         | U/R         |                   |             | 781.00            | 3.9%          | 4.8%            | 1,756.5             | 15.6               | 15.0               | 9.5               | 9.1               | 6.7%          | 6.7%          |
| COGNOR                             | U/R         | 27.50             | 7%          | 8.52              | 1.4%          | 2.2%<br>8.4%    | 340.4               | 12.2               | 8.7                | 7.9               | 6.6               | 0.0%          | 4.3%          |
| LUKA KOPER<br>METALAC              | BUY<br>HOLD | 37.50<br>1,676.00 | 7%<br>2%    | 35.00<br>1,648.00 | 0.0%          | 3.6%            | 490.0<br>27.2       | 8.2<br>4.9         | 9.1<br>4.5         | 5.0<br>2.4        | 5.0<br>2.3        | 7.1%<br>5.5%  | 4.3%<br>6.1%  |
| SNIEZKA                            | U/R         | 1,676.00          | 290         | 83.60             | -0.9%         | 3.0%            | 245.8               | 10.7               | 10.1               | 7.1               | 6.5               | 4.9%          | 5.0%          |
| TEHNOGAS                           | BUY         | 28,141.00         | 13%         | 25,000.00         | 0.0%          | 57.8%           | 243.8               | 7.5                | 6.4                | 3.7               | 3.5               | 2.3%          | 2.7%          |
| METALS & MINING                    | 501         | 20,1-11.00        | 1370        | 25,000.00         | 0.070         | 37.070          | MEDIAN              | 13.3               | 9.7                | 1,2               | 1.0               | 10,2%         | 3.4%          |
| JSW                                | BUY         | 66.98             | 79%         | 37.44             | 0.6%          | -10.9%          | 1,024.5             | 2.0                | 3.7                | -0.5              | -0.9              | 10.2%         | 20.3%         |
| KGHM                               | BUY         | 136.19            | 6%          | 128.00            | 5.4%          | 4.3%            | 5,966.1             | 13.3               | 11.2               | 4.2               | 3.8               | 3.3%          | 3.4%          |
| LW BOGDANKA                        | BUY         | 45.62             | 37%         | 33.18             | 1.3%          | -2.5%           | 263.0               | 23.2               | 9.7                | 1.2               | 1.0               | 19.5%         | 2.2%          |
| OIL, GAS & CHEMICALS               |             |                   |             |                   |               |                 | MEDIAN              | 6.9                | 7.8                | 3.3               | 3.5               | 6.1%          | 6.2%          |
| GRUPA AZOTY                        | U/R         |                   |             | 22.80             | 1.1%          | -7.7%           | 527.1               | na                 | 14.7               | 11.9              | 6.2               | na            | na            |
| NIS                                | BUY         | 887.00            | 3%          | 860.00            | 0.9%          | 5.9%            | 1,197.2             | 4.1                | 4.3                | 2.1               | 2.2               | 8.5%          | 6.2%          |
| OMV PETROM                         | HOLD        | 0.5700            | -16%        | 0.68              | 0.4%          | 17.5%           | 8,465.2             | 6.9                | 7.9                | 3.3               | 4.1               | 5.8%          | 6.1%          |
| ORLEN                              | BUY         | 65.90             | -3%         | 67.95             | 0.5%          | 3.7%            | 18,384.5            | 4.8                | 4.6                | 2.8               | 2.9               | 6.1%          | 6.1%          |
| PETROL                             | BUY         | 30.70             | 10%         | 27.80             | 1.1%          | 19.3%           | 1,160.0             | 8.4                | 8.0                | 3.9               | 3.7               | 6.1%          | 7.2%          |
| ROMGAZ                             | BUY         | 50.00             | -10%        | 55.40             | -0.2%         | 10.6%           | 4,297.5             | 8.3                | 7.8                | 3.7               | 3.5               | 6.6%          | 7.1%          |
| TECHNOLOGY                         | DID.        |                   |             |                   |               |                 | MEDIAN              | 25.6               | 14.8               | 9.5               | 7.9               | 0.0%          | 0.0%          |
| ML SYSTEM<br>SUNEX                 | BUY<br>HOLD | 87.20<br>12.00    | 106%        | 42.30<br>11.70    | 1.7%<br>1.4%  | -21.7%<br>0.5%  | 63.9<br>55.3        | 70.8<br>11.4       | 33.2<br>9.6        | 7.7<br>9.5        | 5.7<br>7.9        | 0.0%<br>1.6%  | 0.0%<br>1.3%  |
| VIGO PHOTONICS                     | BUY         | 600.00            | 3%          | 580.00            | 1.0%          | 18.4%           | 99.3                | 25.6               | 14.8               | 13.9              | 9.1               | 0.0%          | 0.0%          |
| TELECOMS, MEDIA & IT               | 501         | 000.00            | 3,0         | 300.00            | 1.070         | 10.170          | MEDIAN              | 14.0               | 8.4                | 5.1               | 4.9               | 3.0%          | 3.8%          |
| AB                                 | BUY         | 91.90             | -196        | 93.00             | 0.4%          | 27.1%           | 350.8               | 8.5                | 7.9                | 5.6               | 5.3               | 2.6%          | 3.5%          |
| ASSECO POLAND                      | U/R         |                   |             | 80.50             | -0.6%         | 10.1%           | 1,557.1             | 14.0               | 12.2               | 4.3               | 4.1               | 3.6%          | 3.8%          |
| ATM GRUPA                          | HOLD        | 3.62              | 13%         | 3.19              | -1.2%         | -9.9%           | 62.7                | 7.3                | 6.7                | 2.6               | 2.7               | 8.8%          | 10.7%         |
| BITTNET SYSTEMS                    | BUY         | 0.28              | 9%          | 0.26              | -0.8%         | -7.2%           | 27.4                | 7.4                | 4.0                | 3.9               | 1.9               | 0.0%          | 0.0%          |
| CYBER_FOLKS                        | BUY         | 100.30            | -6%         | 106.50            | -2.3%         | 21.9%           | 351.9               | 23.7               | 18.9               | 12.9              | 10.7              | 1.3%          | 1.7%          |
| CYFROWY POLSAT                     | HOLD        | 11.50             | 7%          | 10.71             | 1.0%          | -13.1%          | 1,596.3             | 16.0               | 6.4                | 6.1               | 4.9               | 0.0%          | 0.0%          |
| HRVATSKI TELEKOM                   | HOLD        | 25.90             | -15%        | 30.40             | 0.0%          | 11.4%           | 2,370.5             | 16.9               | 16.0               | 5.1               | 5.1               | 4.3%          | 4.6%          |
| ORANGE POLSKA                      | BUY         | 9.30              | 13%         | 8.20              | 1.2%          | 0.8%            | 2,509.2             | 10.7               | 8.4                | 3.7               | 3.3               | 6.1%          | 9.1%          |
| SAFETECH INNOVATIONS               | HOLD        | 2.60              | 4%          | 2.51              | -0.8%         | -2.3%           | 33.6                | 6.9                | 5.2                | 4.7               | 3.6               | 7.2%          | 12.7%         |
| TEXT                               | U/R         | 75.20             | 260/        | 99.00             | 6.5%          | -13.1%          | 594.1               | na<br>26.4         | na                 | na                | na                | na<br>4 200   | na<br>4 For   |
| VERCOM                             | BUY<br>HOLD | 75.30<br>115.00   | -36%<br>-9% | 117.00<br>126.60  | 0.0%          | 49.6%           | 606.2               | 26.1               | 20.8<br>15.4       | 16.9              | 20.7              | 1.2%          | 1.5%          |
| WIRTUALNA POLSKA                   | HOLD        | 115.00            | -9%         | 126.60            | 1.8%          | 4.1%            | 869.8               | 19.4               |                    | 8.6               | 7.6               | 3.0%          | 5.1%          |
| TRAVEL & LEISURE<br>ENTER AIR      | BUY         | 63.50             | -6%         | 67.70             | 3.2%          | 32.2%           | MEDIAN<br>276.8     | <b>11.0</b><br>6.0 | <b>10.9</b><br>7.1 | <b>5.9</b><br>5.4 | <b>5.7</b><br>5.0 | 2.9%<br>2.2%  | 0.0%          |
| RAINBOW TOURS                      | BUY         | 50.20             | -6%         | 78.80             | 6.5%          | 32.2%           | 267.2               | 11.0               | 10.9               | 6.3               | 5.9               | 2.2%          | 0.0%          |
| VALAMAR RIVIERA                    | BUY         | 4.80              | -9%         | 5.28              | 0.4%          | 11.9%           | 649.6               | 22.7               | 18.7               | 5.9               | 5.7               | 4.7%          | 5.7%          |
| VIDEO GAMES                        |             | 4.00              | 3,0         | 5.20              | 0.170         | 11.570          | MEDIAN              | 7.7                | 7.7                | 5.5               | 3.7               | 0.0           | 0.1           |
| 11 BIT STUDIOS                     | BUY         | 840.00            | 62%         | 520.00            | -0.8%         | -3.9%           | 292.9               | 6.5                | 5.7                | 4.2               | 3.0               | 0.0%          | 0.0%          |
| CD PROJEKT                         | SELL        | 90.00             | -23%        | 116.90            | 2.5%          | 1.7%            | 2,721.9             | 56.4               | 146.6              | 41.0              | 85.9              | 1.4%          | 0.8%          |
| CREEPY JAR                         | HOLD        | 758.83            | 32%         | 575.00            | 0.2%          | -3.8%           | 93.7                | 6.9                | 6.3                | 4.0               | 3.2               | 3.1%          | 7.3%          |
| HUUUGE                             | U/R         |                   |             | 26.45             | -1.9%         | -1.3%           | 413.8               | 3.9                | 7.8                | 1.7               | 0.0               | na            | na            |
| PCF GROUP                          | HOLD        | 48.73             | 120%        | 22.10             | 0.0%          | -25.0%          | 185.1               | 9.3                | 7.8                | 6.9               | 6.3               | 1.5%          | 1.6%          |
| PLAYWAY                            | BUY         | 475.61            | 63%         | 292.00            | 1.0%          | -8.8%           | 449.1               | 9.3                | 7.7                | 7.3               | 6.0               | 9.4%          | 10.8%         |
| TEN SQUARE GAMES                   | U/R         |                   |             | 95.65             | -0.4%         | -0.8%           | 163.5               | 8.5                | 9.0                | 6.7               | 0.0               | 13.9%         | 10.5%         |
| ULTIMATE GAMES                     | BUY         | 17.00             | 49%         | 11.40             | 1.8%          | 14.0%           | 13.9                | 4.6                | 4.4                | 4.4               | 4.1               | 7.5%          | 10.8%         |
| WASTE UTILITIES                    |             |                   |             |                   |               |                 | MEDIAN              | 13.8               | 13.2               | 9.8               | 8.8               | 0.0           | 0.1           |
| MO-BRUK                            | BUY         | 330.25            | -3%         | 340.50            | 3.5%          | 2.9%            | 278.8               | 13.8               | 13.2               | 9.8               | 8.8               | 0.0           | 0.1           |

Please note that the multiples for companies with recommendation U/R are based on consensus expectations

# **RECOMMENDATIONS ISSUED**

|   |            |                        |                          | Price at              | Fair Value            | Previous        | Recomm-      |                                |
|---|------------|------------------------|--------------------------|-----------------------|-----------------------|-----------------|--------------|--------------------------------|
| Analy:  | Validity   | Time                   | Date                     | issuance              | (local)               | recomm-         | endation     | Company                        |
| Marcin Nowa                                     |            | 07:30 CEST             | 02/04/2024               | (local)               |                       | endation<br>BUY | Dropped      | POINTPACK                      |
| Robert M  | 12M        | 07:01 CET              | 29/03/2024               | 854.00                | 1,025.91              | BUY             | BUY          | CEZ                            |
| Marek Szymańs                                   | 12M        | 07:41 CET              | 21/03/2024               | 13,730.00             | 15,800.00             | BUY             | BUY          | LPP                            |
| Adrian Górnia                                   | 12M        | 07:35 CET              | 20/03/2024               | 8.26                  | 11.15                 | BUY             | BUY          | MARVIPOL DEVELOPMENT           |
| Marek Szymańs                                   | 12M        | 17:03 CET              | 15/03/2024               |                       |                       | BUY             | U/R          | LPP                            |
| Michał Wojciechowski, Marcin Nowa               | 4014       | 08:29 CET              | 15/03/2024               | 20.00                 | 27.20                 | BUY             | U/R          | HUUUGE                         |
| Adrian Górnia                                   | 12M<br>12M | 07:28 CET              | 29/02/2024               | 28.90                 | 37.20                 | BUY             | BUY          | ARCHICOM                       |
| Vladan Pavlov<br>Łukasz Kosiars                 | 12M        | 12:57 CET<br>07:30 CET | 26.02.2024<br>21.02.2024 | 114.00<br>59.20       | 138.00<br>99.30       | BUY             | BUY<br>BUY   | NLB BANKA<br>RYVU THERAPEUTICS |
| Michał Wojciechows                              | 12M        | 07:38 CET              | 19.02.2024               | 484.00                | 600.00                | БОТ             | BUY          | VIGO PHOTONICS                 |
| Marek Szymańs                                   | 12M        | 08:34 CET              | 09/02/2024               | 1.36                  | 1.35                  | HOLD            | HOLD         | MIRACULUM                      |
| Vladan Pavlov                                   | 12M        | 07:30 CET              | 08/02/2024               | 115.50                | 111.00                |                 | HOLD         | KRKA                           |
| Vladan Pavlov                                   | 12M        | 07:30 CET              | 08/02/2024               | 93.00                 | 117.00                |                 | BUY          | NLB BANKA                      |
| Vladan Pavlov                                   | 12M        | 07:30 CET              | 08/02/2024               | 25.00                 | 30.70                 |                 | BUY          | PETROL                         |
| Vladan Pavlov                                   | 12M        | 07:30 CET              | 08/02/2024               | 23.80                 | 20.00                 |                 | SELL         | CINKARNA CELJE                 |
| Vladan Pavlov                                   | 12M        | 07:30 CET              | 08/02/2024               | 35.00                 | 37.50                 |                 | BUY          | LUKA KOPER                     |
| Marek Szymańs                                   | 12M        | 07:50 CET              | 05/02/2024               | 16,010.00             | 18,500.00             | BUY             | BUY          | LPP                            |
| Marek Szymańs                                   | 12M        | 07:50 CET              | 05/02/2024               | 59.40                 | 57.10                 | BUY             | HOLD         | CCC<br>LW BOGDANKA             |
| Robert M<br>Michał Wojciechowski, Marcin Nowa   | 12M<br>12M | 07:00 CET<br>07:43 CET | 11/01/2024<br>20/12/2023 | 33.72<br>27.00        | 45.62<br>35.00        | SELL<br>BUY     | BUY<br>BUY   | HUUUGE                         |
| Michał Wojciechowski, Marcin Nowa               | 12M        | 07:43 CET              | 20/12/2023               | 102.00                | 125.00                | BUY             | BUY          | TEN SQUARE GAMES               |
| Adrian Górnia                                   | 12M        | 08:36 CET              | 12/12/2023               | 7.20                  | 10.07                 | BUY             | BUY          | MARVIPOL DEVELOPMENT           |
| Robert M  | 12M        | 07:00 CET              | 11/12/2023               | 44.91                 | 66.98                 | BUY             | BUY          | JSW                            |
| Tomasz Kasowic                                  | 12M        | 07:30 CET              | 30/11/2023               | 59.60                 | 65.90                 | HOLD            | BUY          | ORLEN                          |
| Marta Czajkowska-Bałdyg                         | 12M        | 08:46 CET              | 16/11/2023               | 69.24                 | 97.60                 | BUY             | BUY          | ALIOR BANK                     |
| Marta Czajkowska-Bałdyg                         | 12M        | 08:46 CET              | 16/11/2023               | 7.45                  | 8.65                  | BUY             | BUY          | MILLENNIUM                     |
| Marta Czajkowska-Bałdyg                         | 12M        | 08:46 CET              | 16/11/2023               | 469.00                | 611.60                | BUY             | BUY          | SANTANDER BANK PL              |
| Marta Czajkowska-Bałdyg                         | 12M        | 08:46 CET              | 16/11/2023               | 528.80                | 637.90                | BUY             | BUY          | MBANK                          |
| Marta Czajkowska-Bałdyg                         | 12M        | 08:46 CET              | 16/11/2023               | 129.75                | 183.50                | BUY             | BUY          | PEKAO                          |
| Marta Czajkowska-Bałdyg                         | 12M        | 08:46 CET              | 16/11/2023               | 43.74                 | 60.00                 | BUY             | BUY          | PKO BP                         |
| Robert M  | 12M        | 08:46 CET              | 16/11/2023               | 61.85                 | 67.80                 | HOLD            | HOLD         | ORLEN                          |
| Tomasz Kasowio<br>Vladan Pavlov                 | 12M<br>12M | 08:46 CET<br>08:46 CET | 16/11/2023<br>16/11/2023 | 0.55<br>779.00        | 0.57<br>887.00        | HOLD<br>BUY     | HOLD<br>BUY  | OMV PETROM<br>NIS              |
| Robert M  | 12M        | 08:46 CET              | 16/11/2023               | 7.00                  | 6.15                  | BUY             | SELL         | PGE                            |
| Robert M  | 12M        | 08:46 CET              | 16/11/2023               | 3.68                  | 3.14                  | BUY             | SELL         | TAURON                         |
| Robert M  | 12M        | 08:46 CET              | 16/11/2023               | 7.00                  | 5.78                  | BUY             | SELL         | ENEA                           |
| Robert M  | 12M        | 08:46 CET              | 16/11/2023               | 986.50                | 1,185.75              | SELL            | BUY          | CEZ                            |
| Ionut Gavris, Florin-Adrian Ciocoi, CF          | 12M        | 08:46 CET              | 16/11/2023               | 118.80                | 125.50                | BUY             | HOLD         | HIDROELECTRICA                 |
| Ionut Gavris, Florin-Adrian Ciocoi, CF          | 12M        | 08:46 CET              | 16/11/2023               | 47.55                 | 52.00                 | BUY             | HOLD         | NUCLEARELECTRICA               |
| Robert M  | 12M        | 08:46 CET              | 16/11/2023               | 50.44                 | 74.74                 | SELL            | BUY          | JSW                            |
| Robert M.                                       | 12M        | 08:46 CET              | 16/11/2023               | 112.40                | 136.19                | SELL            | BUY          | KGHM                           |
| Robert M  | 12M        | 08:46 CET              | 16/11/2023               | 36.18                 | 30.76                 | SELL            | SELL         | LW BOGDANKA                    |
| Marek Szymańs                                   | 12M        | 08:46 CET              | 16/11/2023               | 30.40<br>10.34        | 36.90                 | BUY<br>BUY      | BUY<br>BUY   | ALLEGRO<br>INPOST              |
| Marek Szymańs<br>Marcin Nowa                    | 12M<br>12M | 08:46 CET<br>08:46 CET | 16/11/2023<br>16/11/2023 | 43.80                 | 12.30<br>67.50        | BUY             | BUY          | POINTPACK                      |
| Ionut Gavr                                      | 12M        | 08:46 CET              | 16/11/2023               | 13.16                 | 15.60                 | БОТ             | BUY          | PURCARI WINERIES               |
| Ionut Gavris, Florin-Adrian Ciocoi, CF          | 12M        | 08:46 CET              | 16/11/2023               | 20.20                 | 23.28                 | BUY             | BUY          | SPHERA FRANCHISE               |
| Vladan Pavlov                                   | 12M        | 08:46 CET              | 16/11/2023               | 146.00                | 90.00                 | SELL            | SELL         | PODRAVKA                       |
| Vladan Pavlov                                   | 12M        | 08:46 CET              | 16/11/2023               | 52.00                 | 59.80                 | BUY             | BUY          | ATLANTIC GRUPA                 |
| Michał Wojciechowski, Marcin Nowa               | 12M        | 08:46 CET              | 16/11/2023               | 114.00                | 90.00                 | HOLD            | SELL         | CD PROJEKT                     |
| Vladan Pavlov                                   | 12M        | 08:46 CET              | 16/11/2023               | 26.20                 | 25.90                 | HOLD            | HOLD         | HRVATSKI TELEKOM               |
| Marcin Nowa                                     | 12M        | 08:46 CET              | 16/11/2023               | 111.00                | 115.00                | HOLD            | HOLD         | WIRTUALNA POLSKA               |
| Marcin Nowak, Michał Wojciechows                | 12M        | 08:46 CET              | 16/11/2023               | 3.46                  | 3.70                  | BUY             | HOLD         | ATM GRUPA                      |
| Łukasz Kosiars                                  | 12M        | 08:46 CET              | 16/11/2023               | 81.00                 | 100.30                | BUY<br>HOLD     | BUY<br>BUY   | CYBER FOLKS                    |
| Łukasz Kosiars<br>Ionut Gavr                    | 12M<br>12M | 08:46 CET<br>08:46 CET | 16/11/2023<br>16/11/2023 | 62.10<br>0.25         | 75.30<br>0.28         | BUY             | BUY          | VERCOM<br>BITTNET SYSTEMS      |
| Adrian Górnia                                   | 12M        | 08:46 CET              | 16/11/2023               | 5.02                  | 5.96                  | SELL            | BUY          | GTC                            |
| Adrian Gornia                                   | 12M        | 08:46 CET              | 16/11/2023               | 176.70                | 183.00                | BUY             | BUY          | DOM DEVELOPMENT                |
| Adrian Górnia                                   | 12M        | 08:46 CET              | 16/11/2023               | 58.00                 | 71.00                 | BUY             | BUY          | ATAL                           |
| Adrian Górnia                                   | 12M        | 08:46 CET              | 16/11/2023               | 4.87                  | 6.16                  | BUY             | BUY          | DEVELIA                        |
| Adrian Górnia                                   | 12M        | 08:46 CET              | 16/11/2023               | 23.20                 | 24.20                 | HOLD            | HOLD         | LOKUM DEWELOPER                |
| Łukasz Kosiars                                  | 12M        | 08:46 CET              | 16/11/2023               | 54.50                 | 81.70                 | BUY             | BUY          | RYVU THERAPEUTICS              |
| Łukasz Kosiars                                  | 12M        | 08:46 CET              | 16/11/2023               | 14.58                 | 15.50                 | HOLD            | HOLD         | CELON PHARMA                   |
| Łukasz Kosiars                                  | 12M        | 08:46 CET              | 16/11/2023               | 17.86                 | 25.60                 | HOLD            | BUY          | MOLECURE                       |
| Łukasz Kosiars                                  | 12M        | 08:46 CET              | 16/11/2023               | 70.90                 | 81.40                 | BUY             | BUY          | POLTREG                        |
| Łukasz Kosiars<br>Łukasz Kosiars                | 12M<br>12M | 08:46 CET<br>08:46 CET | 16/11/2023<br>16/11/2023 | 721.00<br>59.40       | 849.00<br>70.00       | HOLD<br>BUY     | BUY<br>BUY   | NEUCA<br>SELVITA               |
| Łukasz Kosiars<br>Łukasz Kosiars                | 12M        | 08:46 CET              | 16/11/2023               | 66.60                 | 106.60                | HOLD            | BUY          | SYNEKTIK                       |
| Łukasz Kosiars                                  | 12M        | 08:46 CET              | 16/11/2023               | 57.40                 | 72.70                 | BUY             | BUY          | VOXEL                          |
| Łukasz Kosiars                                  | 12M        | 08:46 CET              | 16/11/2023               | 165.00                | 230.20                | BUY             | BUY          | SCOPE FLUIDICS                 |
| Łukasz Kosiars                                  | 12M        | 08:46 CET              | 16/11/2023               | 27.40                 | 41.20                 | BUY             | BUY          | MEDICALGORITHMICS              |
| Ionut Gavris, Florin-Adrian Ciocoi, CF          | 12M        | 08:46 CET              | 16/11/2023               | 4.33                  | 5.64                  | BUY             | BUY          | MEDLIFE                        |
| Robert M  | 12M        | 08:46 CET              | 16/11/2023               | 287.50                | 330.25                | BUY             | BUY          | MO-BRUK                        |
| Adrian Górnia                                   | 12M        | 08:46 CET              | 16/11/2023               | 41.00                 | 63.50                 | BUY             | BUY          | ENTER AIR                      |
| Adrian Górnia                                   | 12M        | 08:46 CET              | 16/11/2023               | 43.30                 | 50.20                 | BUY             | BUY          | RAINBOW TOURS                  |
| Vladan Pavlov                                   | 12M        | 08:46 CET              | 16/11/2023               | 4.27                  | 4.80                  | BUY             | BUY          | VALAMAR RIVIERA                |
| Robert M  | 12M        | 08:46 CET              | 16/11/2023               | 7.66                  | 10.00                 | BUY             | BUY          | MIRBUD                         |
| Vladan Pavlov                                   | 12M        | 08:46 CET              | 16/11/2023               | 53.40<br>1,588.00     | 52.80<br>1,676.00     | HOLD<br>HOLD    | HOLD<br>HOLD | ADRIS GRUPA<br>METALAC         |
|   | 12M        | 08:46 CET              | 16/11/2023               |                       |                       |                 | BUY          | TEHNOGAS                       |
| Vladan Pavlov<br>Vladan Pavlov                  | 12M        | 08:46 CFT              | 16/11/2023               |                       | 78 141 111            |                 |              |                                |
| Vladan Pavlov<br>Vladan Pavlov<br>Vladan Pavlov | 12M<br>12M | 08:46 CET<br>08:46 CET | 16/11/2023<br>16/11/2023 | 15,959.00<br>7,000.00 | 28,141.00<br>6,429.00 | BUY<br>SELL     | HOLD         | JEDINSTVO SEVOJNO              |



This document has been prepared by IPOPEMA Securities S.A. with its registered seat in Warsaw, Próżna 9, 00-107 Warsaw, Poland, entered into the Register of Entrepreneurs of the National Court Register maintained by the District Court for the City of Warsaw, XII Commercial Division of the National Court Register under entry number KRS 0000230737, the initial capital and paid capital in the amount of PLN 2.993.783,60, NIP 5272468122, www.ipopema.pl. IPOPEMA Securities S.A. is supervised by the Polish Financial Supervision Authority (Komisja Nadzoru Finansowego), Piękna 20, 00-549 Warsaw, Poland.

This document was prepared by IPOPEMA Securities S.A. for information purposes only. This document is addressed to IPOPEMA Securities S.A. clients entitled to receive it on the basis of contracts for the provision of services. This document, using mass media distribution channels, may also reach other investors. It has been produced independently of the company mentioned in this document and any forecasts, opinions and expectations are entirely those of IPOPEMA Securities S.A. Unless otherwise specified, the estimates and opinions contained in the document constitute an independent assessment of IPOPEMA Securities S.A. analysts preparing the document as of the date of issuing the document.

IPOPEMA Securities S.A. prepared this document with the preservation of all adequate diligence, thoroughness and reliability on the basis of publicly available information which IPOPEMA Securities S.A. believes to be reliable. The sources of data are primarily: Bloomberg, Reuters, EPFR, Polska Agencja Prasowa, WSE, Główny Urząd Statystyczny, Narodowy Bank Polski, financial press, online financial and economic services. While due diligence has been taken by IPOPEMA Securities S.A. to ensure that the facts stated herein are accurate and than any forecasts, opinions and expectations contained herein are fair and reasonable, IPOPEMA Securities S.A. has not independently verified all the information given in this document. Accordingly, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this document. The opinions expressed in the document can change without notice and IPOPEMA Securities S.A. is under no obligation to keep these opinion current. None of the IPOPEMA Securities S.A. or any other person accepts any liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith provided that IPOPEMA Securities S.A. has been exercised due diligence and integrity during its preparation. This document may be sent to the mass media, however its copying or publishing in whole or in part as well as dissemination of information enclosed to it is allowed only with prior permission of IPOPEMA Securities S.A. This document nor any copy hereof is not to be distributed directly or indirectly in the United States, Australia, Canada or Japan, subject to the following section.

Important disclosures for U.S. Persons: Auerbach Grayson & Company Inc. may distribute this document in the U.S. This document is provided for distribution to Major U.S. Institutional Investors in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended and may not be furnished to any other person in the U.S. Each Major U.S. Institutional Investor that receives this document shall not distribute or provide it to any other person. Under no circumstances should any U.S. recipient of this document effect any transaction to buy or sell securities or related financial instruments based on the information provided in this document should do so only through Auerbach Grayson & Company Inc. 25 West 45th Street, Floor 16, New York, NY 10036 U.S. which is a registered broker dealer in the U.S. IPOPEMA Securities S.A. is not a registered broker-dealer in the U.S. and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. IPOPEMA Securities S.A. and its research analysts are not associated persons of Auerbach Grayson & Company, nor are they affiliated with Auerbach Grayson & Company. The author of this document whose name appears in this document is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"), is not subject to the SEC rules on research analysts and is not subject FINRA's rules on debt research analysts and debt research reports, equity research analysts and equity research reports. U.S. recipients should take into account that information on non-U.S. securities or related financial instruments discussed in this document may be limited. The financial instruments of non-U.S. issuers may not be registered with, or be subject to the regulations of, the SEC. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the U.S.

This document does not constitute any offer to sell or induce any offer to buy or sell any financial instruments, cannot be relied on in connection with any contract or liability and does not constitute advertising or promotion of a financial instrument or the company. Investment decisions should only be made on the basis of a prospectus or other publicly available information and materials.

The document was prepared without taking into account the needs and situation of the recipients of the document. When preparing the document, IPOPEMA Securities S.A. does not examine the recipient's investment objectives, risk tolerance level, time horizon and financial standing of the investors. The company or the financial instruments discussed in the document may not be suitable for the users of the document, i.e. it may not be suitable for the specific objectives and time horizon or the financial situation. Information included in the document cannot be regarded as a substitute for obtaining investment advice service. The value of financial instruments may fluctuate, including declines. Changes in FX rates may have an adverse effect on the value of investments. The investment in financial instruments is linked to investment risks including loss of entire or part of the invested capital. Past performance is not necessarily indicative of future results. IPOPEMA Securities S.A. points out that the price of financial instruments is affected by many different factors that are or may be independent of the company and the results of its operations. These include, among others changing economic, legal, political and tax conditions. IPOPEMA Securities S.A. may have issued in the past or may issue other documents in the future, presenting other conclusions, not consistent with those presented herein document. Such documents reflect different assumptions, points of view and analytical methods adopted by the analysts preparing them.

Investors should be aware that IPOPEMA Securities S.A. or its related entities may have a conflict of interest that could affect this document's objectivity. The investor should assume that IPOPEMA Securities S.A. or its related entities may provide services in favour of the company and obtain remuneration on this account. They may also have another financial interest with respect to the company. IPOPEMA Securities S.A. or its related entities may seek to do business with the company or other entities mentioned in this document. IPOPEMA Securities S.A. has an organizational structure and internal regulations in place to ensure that the client's interests are not compromised in the event of a conflict of interests, in relation to preparing this document. Conflict of interest management policy is available on the website at <a href="https://www.ipopemasecurities.pl/analizy-i-rekomendacje.p162">https://www.ipopemasecurities.pl/analizy-i-rekomendacje.p162</a>. This document was prepared irrespective and independently of the interests of IPOPEMA Securities S.A., the company that is the subject of this document and holder of financial instrument issued by aforementioned company. IPOPEMA Securities S.A., its shareholders, employees and associates may hold long or short positions in the company's financial instruments or other financial instruments related to the company's financial instruments.

On the order of the Warsaw Stock Exchange S.A. ("WSE"), IPOPEMA Securities S.A. creates analytical materials for the following companies: Marvipol Development S.A., Medicalgorithmics S.A., Miraculum S.A., ML System S.A., Scope Fluidics S.A., Sunex S.A., VIGO Photonics S.A. The WSE has proprietary copyrights to these materials. For the preparation of IPOPEMA Securities S.A. receives remuneration from the WSE. Information on the program is available on the website <a href="https://www.gpw.pl/gpwpa">https://www.gpw.pl/gpwpa</a>.

On the order of the Bursa de Valori Bucuresti S.A. ("BVB"), IPOPEMA Securities S.A. creates analytical materials for the following companies: Bittnet Systems S.A. and Impact Developer & Contractor S.A. The BVB has proprietary copyrights to these materials. For the preparation of IPOPEMA Securities S.A. receives remuneration from the BVB.

IPOPEMA Securities S.A. uses a number of valuation methodologies including discounted cash flows models (such as discounted operating earnings or dividend discount model), and earnings and cash-flow based models, which are often related to comparisons with selected peer companies. Cash flow models encapsulate the cash streams forecast to flow to a company, and are widely used in the investment industry. Peer comparisons factor in amongst other factors, differential growth rates, and indicate how expensive one company might appear relative to a chosen comparator. The subjective opinions of the report's author or authors, formed by their knowledge and experience, play a significant role in the valuation. Also included are assumptions on numerous economic variables, particularly interest rates, inflation and exchange rates and varying these assumptions could results in significantly different opinions. The strength of the earnings and cash flow based models is the closer attention to a company on a standalone basis, and tying the valuation to its fundamental value. The weakness of such method is the number of assumptions, which need to be adopted and resulting sensitivity to those assumptions. The peer comparisons methods are less dependent on the analyst's judgment as to the individual parameters, however the problem with this method appears when the peer comparator is over- or undervalued. Moreover, leading multiples (based on the future earnings, book values, operating profit or cash flows) include an analyst's estimate of those values.

This document was not transferred to the company prior to its publication. This document was prepared according to the author's own view, assumptions and knowledge.

Recommendations issued by IPOPEMA Securities S.A. they are valid for a period of 12 months from the date of issue, unless they are updated during this period. IPOPEMA Securities S.A. updates the issued recommendations depending on the market situation and subjective analysts' assessment.

List of all recommendations regarding any financial instrument or issuer that have been disseminated within the last 12 months by IPOPEMA Securities S.A. is available on the website at <a href="https://www.ipopemasecurities.pl/analizy-i-rekomendacje.p162">https://www.ipopemasecurities.pl/analizy-i-rekomendacje.p162</a>.

The date and the time stated on the front page is the date of the preparation of this document. The price used throughout the recommendation to calculate adequate ratios is the "last" price stated on the front page of this document.

The definitions of terms used in the document include:

NII - Net interest income - interest income minus interest expense.

Net F&C - Net fee and commission income - fee and commission income minus fee and commission expense.

LLP - loan loss provisions - an expense set aside as an allowance for bad loans.



 $\ensuremath{\mathsf{NPL}}$  – non-performing loan – loans that are in default or close to be in default.

 ${\sf Cost/Income-operating\ expenses\ divided\ by\ total\ banking\ revenue.}$ 

ROE – return on equity – net income (or adjusted net income) divided by the average shareholders' equity.

ROA - return on assets - net income (or adjusted net income) divided by the average assets.

EBIT - earnings before interests and tax.

EBITDA - earnings before interests, tax, depreciation and amortization.

EPS – earnings per share – the net income (or adjusted net income divided by the number of shares outstanding.

P/E – price to earnings ratio – price divided by earnings per share.

PEG – P/E ratio divided by the annual EPS growth, usually over a certain period of time.

CAGR - compound annual growth rate.

BVPS – book value per share, the book value of the Company's equity divided by the number of shares outstanding.

P/BV - price to book value - price divided by the BVPS.

DPS - dividend per share - dividend of a given year divided by the number of shares outstanding.

 $\ensuremath{\mathsf{DY}}$  – dividend yield – dividend of a given year divided by the current price.

DDM - dividend discount model - a fundamental method of valuation based on the assumption that the value of stock equals the sum of all discounted future dividends.

FV - Fair Value, calculated based on valuation methods outlined in the document.

The author of this document has no conflict of interest with the company that is the subject of this document. The point of view expressed in the document reflects the personal opinion of the author of the document on the analyzed company and its financial instruments. Investors should be aware that flexible part of the author's compensation may depend on general financial performance of IPOPEMA Securities S.A.

IPOPEMA Securities S.A. shall act with due diligence, honestly, fairly, professionally and in accordance with the provisions of the applicable law.

IPOPEMA Securities S.A. does not guarantee achieving the investor's investment objective, the performance of company or prospective prices referred to herein.

When applying ratings for companies following criteria are used with regards to the difference between IPOPEMA's FV and company's price at the date of recommendation:

| Rating | Difference between FV and price at recommendation |
|--------|---|
| Buy    | Above 10%   |
| Hold   | In between (and including) -10% and 10%           |
| Sell   | Below -10%  |

| IPOPEMA Research - Distribution by rating category (1 January – 31 March 2024) |        |      |  |
|--|--------|------|--|
|  | Number | %    |  |
| Buy  | 12     | 75%  |  |
| Hold   | 3      | 19%  |  |
| Sell   | 1      | 6%   |  |
| Total  | 16     | 100% |  |

| Warsaw Sales Team Contact |                  | Warsaw Research Team Contact |                   |
|---------------------------|------------------|------------------------------|-------------------|
| Stanisław Waczkowski      | +48 22 534 10 00 | Robert Maj                   | +48 22 236 92 90  |
| Arkadiusz Łabuńko         | +48 22 534 10 40 | Marcin Nowak                 | +48 22 236 92 44  |
| Łukasz Surowiec           | +48 22 534 10 99 | Marta Czajkowska-Bałdyga     | +48 509 318 601   |
| Arnold Teterycz           | +48 22 534 10 20 | Ionut Gavris                 | +48 514 995 141   |
| Paweł Wiśniewski          | +48 22 534 10 60 | Adrian Górniak               | +48 514 995 073   |
| Maciej Kowalski           | +48 22 534 10 58 | Hubert Kaczmarski            | +48 514 985 103   |
|                           |                  | Tomasz Kasowicz              | +48 514 985 232   |
|                           |                  | Łukasz Kosiarski             | +48 882 108 382   |
|                           |                  | Vladan Pavlovic              | +381 65 25 15 979 |
|                           |                  | Marcin Sulewski, CFA         | +48 889 695 633   |
|                           |                  | Marek Szymański              | +48 22 236 94 12  |
|                           |                  | Michał Wojciechowski         | +48 22 236 92 69  |

| International Equity Sales |                  |  |
|----------------------------|------------------|--|
| Robert Szucsich            | +48 22 236 92 63 |  |